Home Cart Sign in  
Chemical Structure| 2353-33-5 Chemical Structure| 2353-33-5

Structure of Decitabine
CAS No.: 2353-33-5

Chemical Structure| 2353-33-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Decitabine is a potent inhibitor of DNA methyltransferase with IC50 of 438 nM and 4.38 nM in HL-60 and KG1a cells, respectively.

Synonyms: 5-Aza-2'-deoxycytidine; 5AZA; 5-aza-dCyd

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Decitabine

CAS No. :2353-33-5
Formula : C8H12N4O4
M.W : 228.21
SMILES Code : OC[C@@H]1[C@H](C[C@H](N2C(N=C(N=C2)N)=O)O1)O
Synonyms :
5-Aza-2'-deoxycytidine; 5AZA; 5-aza-dCyd
InChI Key :XAUDJQYHKZQPEU-KVQBGUIXSA-N
Pubchem ID :451668

Safety of Decitabine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Decitabine

epigenetics

Isoform Comparison

Biological Activity

Target
  • DNA Methyltransferase

In Vitro:

Cell Line
Concentration Treated Time Description References
Alb-R26Met HCC cells 0.3 µM 48 h Decitabine treatment does not affect the viability of Alb-R26Met HCC cells but interferes with their tumorigenic properties, as evidenced by reduced colony numbers in anchorage-independent growth, reduced number and size of foci in anchorage-dependent growth, and reduced tumor spheres in self-renewal conditions. PMC6082886
T-ALL cells 1 μM 48 h To evaluate the effect of Decitabine on T-ALL cell lines, results showed that Decitabine significantly upregulated tumor suppressor genes (e.g., BMF and BBC3) and downregulated the MYC pathway. PMC7116343
HGC27 cells 20μM 72 h Decitabine synergized with COX inhibitors to reduce cell viability in HGC27 cells PMC6735505
MKN1 cells 20μM 72 h Decitabine synergized with COX inhibitors to reduce cell viability in MKN1 cells PMC6735505
HCT116 cells 2.5 μM 24–72 h Inhibited methylation and increased HOXB13 expression PMC6882800
RKO cells 2.5 μM 24–72 h Inhibited methylation and increased HOXB13 expression PMC6882800
PUER cells 0.5 µM Decitabine addition concurrent with OHT attenuated the repression of stem cell genes and the activation of differentiation genes, thereby maintaining self-renewal of hematopoietic precursors PMC2884053
Human CD34+ hematopoietic precursors 0.5 µM Decitabine addition concurrent with G-CSF attenuated the repression of stem cell genes and the activation of differentiation genes, thereby maintaining self-renewal of hematopoietic precursors PMC2884053
ML-2 cells 100 nM 24 h Quantitative determination of Decitabine incorporation into DNA, showing significant incorporation of Decitabine PMC4231731
K562 cells 100 nM 24 h Quantitative determination of Decitabine incorporation into DNA, showing significant incorporation of Decitabine PMC4231731
U937 cells 100 nM 24 h Quantitative determination of Decitabine incorporation into DNA, showing significant incorporation of Decitabine PMC4231731
HL-60 cells 100 nM 24 h Quantitative determination of Decitabine incorporation into DNA, showing significant incorporation of Decitabine PMC4231731
KG-1 cells 100 nM 24 h Quantitative determination of Decitabine incorporation into DNA, showing significant incorporation of Decitabine PMC4231731
KG-1a cells 100 nM 24 h Quantitative determination of Decitabine incorporation into DNA, showing significant incorporation of Decitabine PMC4231731
HCT116 cells 100 nM 24 h Quantitative determination of Decitabine incorporation into DNA, showing significant incorporation of Decitabine PMC4231731
MTT cells 10^-4 mol/L VPA and 10^-7 mol/L DAC 2 days Investigate the effects of VPA and DAC on SSTR2 levels and radioligand uptake in MTT cells. Results showed that the combination of VPA and DAC significantly increased SSTR2 levels and radioligand uptake. PMC9800739
MPC cells 10^-4 mol/L VPA and 10^-7 mol/L DAC 2 days Investigate the effects of VPA and DAC on SSTR2 levels and radioligand uptake in MPC cells. Results showed that DAC alone or in combination with VPA increased SSTR2 levels and radioligand uptake. PMC9800739

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
CD-1 mice Not specified Oral gavage 0.4 mg/kg and 1.0 mg/kg Single dose To measure plasma drug levels of Decitabine, results showed significantly lower drug levels in male mice compared to females PMC3577958
Nude mice Alb-R26Met HCC cell xenograft model Intraperitoneal injection 2.5 mg/kg Twice a week for three weeks Decitabine treatment significantly reduced the tumor volume of Alb-R26Met HCC cells in nude mice, and the dose was not toxic. PMC6082886
Mice T-ALL patient-derived xenograft (PDX) models Not specified 0.5 mg/kg Once daily for 5 days, followed by 2 days off, for two cycles To evaluate the effect of Decitabine on T-ALL xenograft models, results showed that Decitabine significantly prolonged leukemia-free survival and downregulated the MYC pathway. PMC7116343
Nude mice HGC27 xenograft model Intraperitoneal injection 5mg/kg 3 times per week for 21 days Decitabine synergized with Celecoxib to inhibit HGC27 xenograft tumor growth PMC6735505
Mice MC38 tumor model Intraperitoneal injection 0.2 mg/kg/day 5 consecutive days DAC combined with anti-PD-1 significantly inhibited tumor growth, promoted TILs infiltration, and enhanced CD8+ T cell function PMC10186650

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02564536 Chronic Myelomonocytic Leukemi... More >>a Juvenile Myelomonocytic Leukemia Atypical Chronic Myeloid Leukemia Myeloproliferative Neoplasm Myelodysplastic Syndromes Myelofibrosis Less << Phase 1 Withdrawn(Lack of funding foll... More >>owing full FDA clinical hold) Less << June 30, 2020 -
NCT01130506 Previously Treated Myelodyspla... More >>stic Syndrome Recurrent Adult Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Therapy-Related Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia Less << Phase 1 Completed - United States, Ohio ... More >> Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03240211 PTCL CTCL Phase 1 Recruiting December 2020 United States, New York ... More >> 51 West 51st Street, Suite 200 Recruiting New York, New York, United States, 10019 Contact: Michelle Malanga    212-326-5731    mm4629@cumc.columbia.edu    Italy University of Bologna Not yet recruiting Bologna, Italy Principal Investigator: Pier Luigi Zinzani, MD, PhD          Korea, Republic of Samsung Medical Center Not yet recruiting Seoul, Korea, Republic of Principal Investigator: Won Seog Kim, MD, PhD Less <<
NCT00075010 Leukemia Myel... More >>odysplastic Syndromes Less << Phase 1 Phase 2 Completed - United States, Texas ... More >> M.D. Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02121418 Chronic Myelomonocytic Leukemi... More >>a-2 Myelodysplastic Syndrome Myeloproliferative Neoplasm Untreated Adult Acute Myeloid Leukemia Less << Not Applicable Completed - United States, Montana ... More >> Bozeman Deaconess Hospital Bozeman, Montana, United States, 59715 United States, Washington Kadlec Clinic Hematology and Oncology Kennewick, Washington, United States, 99336 EvergreenHealth Medical Center Kirkland, Washington, United States, 98033 Skagit Valley Hospital Mount Vernon, Washington, United States, 98274 Olympic Medical Center Port Angeles, Washington, United States, 98362 Group Health Cooperative Redmond, Washington, United States, 98052 Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 Multicare Health System Tacoma, Washington, United States, 98415 Wenatchee Valley Hospital and Clinics Wenatchee, Washington, United States, 98801 Less <<
NCT02121418 - Completed - -
NCT03256071 Acute Myeloid Leukemia ... More >> Allogeneic Hematopoietic Stem Cell Transplantation Conditioning Less << Phase 2 Phase 3 Recruiting September 2021 China, Jiangsu ... More >> The First Affiliated Hospital of Soochow University Recruiting Suzhou, Jiangsu, China, 215000 Contact: Xiaowen Tang, MD    +86-512-67781851    xwtang1020@163.com    Principal Investigator: Depei Wu, MD Less <<
NCT01806116 Higher-risk Myelodysplastic Sy... More >>ndrome Relapsed /Refractory Acute Myeloid Leukemia Less << Phase 4 Unknown May 2014 -
NCT03346642 Primary Mediastinal Large B-ce... More >>ll Lymphoma Less << Phase 1 Phase 2 Recruiting October 1, 2019 China, Beijing ... More >> Biotherapeutic Department and Pediatrics Department of Chinese PLA General Hospital Recruiting Beijing, Beijing, China, 100853 Contact: Weidong Han, Doctor    86-10-66937463    hanwdrsw@sina.com    Contact: Qingming Yang, Doctor    86-10-55499341    yangqm@medmail.com.cn    Principal Investigator: Wenying Zhang          Principal Investigator: Qian Mei          Principal Investigator: Yang Liu          Principal Investigator: Weidong Han          Principal Investigator: Qingming Yang          Principal Investigator: Hejin Jia          Principal Investigator: Jing Nie          Principal Investigator: Chunmeng Wang          Principal Investigator: Yan Zhang          Sub-Investigator: Kaichao Feng          Sub-Investigator: Meixia Chen          Sub-Investigator: Lu Shi          Sub-Investigator: Xiang Li          Sub-Investigator: Liang Dong          Biotherapeutic Department of Chinese PLA General Hospital Recruiting Beijing, Beijing, China, 100853 Contact: Weidong Han, Doctor    86-10-66937463    hanwdrsw@sina.com    Contact: Qingming Yang, Doctor    86-10-55499341    yangqm@medmail.com.cn Less <<
NCT01001143 Leukemia, Myeloid, Acute Phase 1 Completed - United States, Missouri ... More >> Washington University School of Medicine St. Louis, Missouri, United States, 63110 Less <<
NCT00791271 Melanoma Phase 1 Terminated - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03377725 Myelodysplastic Syndromes ... More >> P53 Mutation Less << Phase 3 Not yet recruiting November 2020 China ... More >> Ruijin Hospital North Not yet recruiting Shanghai, China Contact: Sujiang Zhang, MD    0086-21-67888761    zbruce.zhang@hotmail.com    Principal Investigator: Sujiang Zhang, MD          Ruijin Hospital Not yet recruiting Shanghai, China Contact: Junmin Li, MD    86-21-64370045 ext 665251    drlijunming@126.com    Principal Investigator: Junming Li, MD          Shanghai Institute of Hematology Not yet recruiting Shanghai, China Contact: Min Lu, Ph.D.    86-21-64370045 ext 610805    min.lu@shsmu.edu.cn    Principal Investigator: Min Lu, Ph.D. Less <<
NCT01378416 - Completed - -
NCT00113321 Myelodysplastic Syndrome|Chron... More >>ic Myelomonocytic Leukemia Less << PHASE2 TERMINATED 2025-11-08 UT MD Anderson Cancer Center, ... More >>Houston, Texas, 77030, United States Less <<
NCT01378416 Leukemia Phase 1 Completed - United States, Missouri ... More >> Washington University School of Medicine St. Louis, Missouri, United States, 63110 Less <<
NCT01751867 Myelodysplastic Syndrome Phase 3 Completed - China ... More >> Beijing, China Chengdu, China Guangdong, China Hangzhou, China Nanjing, China Shanghai, China Suzhou, China Tianjin, China Less <<
NCT01751867 - Completed - -
NCT00113321 Myelodysplastic Syndrome|Chron... More >>ic Myelomonocytic Leukemia Less << PHASE2 TERMINATED 2025-11-08 UT MD Anderson Cancer Center, ... More >>Houston, Texas, 77030, United States Less <<
NCT00619099 - Completed - -
NCT01846624 - Terminated(Accrual factor) - -
NCT03553537 Peripheral T-cell Lymphoma Phase 3 Not yet recruiting July 2021 -
NCT02532010 Acute Myeloid Leukemia (AML) Phase 2 Terminated(The study was put o... More >>n clinical hold by the sponsor since Feb 9th 2016, and was later decided not to re-open due to financial constraints.) Less << - United States, New York ... More >> Weill Cornell Medical College New York, New York, United States, 10021 Less <<
NCT01846624 Acute Myeloid Leukemia (AML) W... More >>ith Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults AML (Adult) With 11q23 (MLL) Abnormalities AML (Adult) With Del (5q) AML (Adult) With Inv (16) (p13; q22) AML (Adult) With t (16;16) (p13; q22) AML (Adult) With t (8; 21) (q22; q22) Secondary AML (Adult) Untreated AML (Adult) Less << Phase 2 Terminated(Accrual factor) - United States, California ... More >> Stanford University School of Medicine Stanford, California, United States, 94305 Less <<
NCT00619099 Myelodysplastic Syndrome Phase 2 Completed - United States, Ohio ... More >> Gabrail Cancer Center Canton, Ohio, United States, 44718 United States, Rhode Island Landmark Medical Center Woonsocket, Rhode Island, United States, 02895 United States, Tennessee Sarah Cannon Research Nashville, Tennessee, United States, 37203 United States, Texas M. D. Anderson Houston, Texas, United States, 77030 Less <<
NCT01876641 Metastatic Melanoma ... More >> Melanoma BRAF-mutated Metastatic Melanoma V600EBRAF-mutated Metastatic Melanoma Less << Phase 1 Terminated(Loss of funding) - United States, Iowa ... More >> University of Iowa Hospitals & Clinics Iowa City, Iowa, United States, 52242 Less <<
NCT00968071 Acute Myelogenous Leukemia ... More >> Myelodysplastic Syndrome Less << Phase 2 Completed - United States, Texas ... More >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03593915 Myelodysplastic Syndromes (MDS... More >>) Less << Phase 1 Phase 2 Recruiting May 2022 United States, Maryland ... More >> Johns Hopkins Not yet recruiting Baltimore, Maryland, United States, 21218 Contact: Amy DeZern, MD          Principal Investigator: Amy DeZern, MD          United States, Texas US Oncology - Texas Oncology - Austin Midtown Recruiting Austin, Texas, United States, 78705 Contact: Jason Melear, MD    512-421-4163       Principal Investigator: Jason Melear, MD          US Oncology - Texas Oncology - San Antonio Medical Center Recruiting San Antonio, Texas, United States, 78240 Contact: Roger Lyons, MD          Principal Investigator: Roger Lyons, MD          US Oncology - Texas Oncology - Tyler Recruiting Tyler, Texas, United States, 75702 Contact: Habte Yimer, MD    903-579-9800       Principal Investigator: Habte Yimer, MD          United States, Washington US Oncology - Northwest Cancer Specialists, P.C. Recruiting Vancouver, Washington, United States, 98684 Contact: David A Smith, MD          Principal Investigator: David A Smith, MD Less <<
NCT00621023 Myelodysplastic Syndrome Phase 2 Completed - United States, North Carolina ... More >> Duke University Medical Center Durham, North Carolina, United States, 27710 Less <<
NCT00968071 - Completed - -
NCT00621023 - Completed - -
NCT02109744 Acute Myelogenous Leukemia PHASE1|PHASE2 COMPLETED 2022-01-01 University of Rochester, Roche... More >>ster, New York, 14642, United States Less <<
NCT02532010 - Terminated(The study was put o... More >>n clinical hold by the sponsor since Feb 9th 2016, and was later decided not to re-open due to financial constraints.) Less << - -
NCT00925132 - Terminated(Change in the numbe... More >>r of approved drugs for metastatic melanoma) Less << - -
NCT00925132 Metastatic Melanoma Phase 1 Phase 2 Terminated(Change in the numbe... More >>r of approved drugs for metastatic melanoma) Less << - United States, Iowa ... More >> University of Iowa Hospitals and Clinics Iowa City, Iowa, United States, 52242 Less <<
NCT02316964 Adult Acute Myeloid Leukemia W... More >>ith 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Recurrent Adult Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Less << Phase 1 Active, not recruiting December 31, 2019 United States, Ohio ... More >> Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio, United States, 43210 Less <<
NCT01455506 Acute Myeloid Leukemia ... More >> Myelodysplastic Syndrome Less << Phase 1 Completed - United States, New Jersey ... More >> Hackensack University Medical Center - John Theurer Cancer Center Hackensack, New Jersey, United States, 07601 Less <<
NCT02685228 Pancreatic Cancer Not Applicable Unknown December 2018 -
NCT03063944 Acute Myeloid Leukemia ... More >> Untreated Adult Acute Myeloid Leukemia Less << Phase 1 Suspended(second DLT in cohort... More >> experience. Cohort is closed and study is being amended in order to re-open) Less << November 2019 United States, Pennsylvania ... More >> Sidney Kimmel Cancer Center at Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19171 Less <<
NCT01720225 Leukemia Phase 2 Active, not recruiting November 2020 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00671697 Myelodysplastic Syndromes and ... More >>Leukemia, Myeloid, Acute Less << Phase 1 Completed - United States, Missouri ... More >> Washington University St. Louis, Missouri, United States, 63110 Less <<
NCT01729845 - Completed - -
NCT01194908 Breast Cancer ... More >> Breast Tumors Breast Neoplasms Less << Phase 1 Phase 2 Terminated(Slow accrual) - United States, Georgia ... More >> Emory University Winship Cancer Institute Atlanta, Georgia, United States, 30329 Less <<
NCT01194908 - Terminated(Slow accrual) - -
NCT02846935 T-cell Lymphoma ... More >> Aggressive B-cell Lymphoma Non-Hodgkin's Lymphomas Indolent B-cell Lymphoma Less << Early Phase 1 Recruiting August 2021 United States, Ohio ... More >> Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Withdrawn Cleveland, Ohio, United States, 44106 Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center Recruiting Cleveland, Ohio, United States, 44195 Contact: Mitchell R Smith, MD, PhD    216-444-4366    smithm14@ccf.org    Principal Investigator: Mitchell R Smith, MD, PhD Less <<
NCT01729845 Previously Treated Myelodyspla... More >>stic Syndrome Recurrent Adult Acute Myeloid Leukemia Less << Phase 1 Phase 2 Completed - United States, Washington ... More >> Kadlec Clinic Hematology and Oncology Kennewick, Washington, United States, 99336 EvergreenHealth Medical Center Kirkland, Washington, United States, 98033 Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 Less <<
NCT01799083 Solid Tumors ... More >>B Cell Lymphoma Less << Phase 1 Phase 2 Unknown December 2017 China, Beijing ... More >> Biotherapeutic Department of Chinese PLA General Hospital Recruiting Beijing, Beijing, China, 100853 Contact: Wei D Han, Doctor    +86-10-66937463    hanwdrsw@sina.com    Contact: Xue C Lu, Doctor    +86-10-66876237    luxuechun@126.com    Sub-Investigator: Yang Liu, Master          Sub-Investigator: Bo Yang, Doctor          Sub-Investigator: Yao Wang, Master          Sub-Investigator: Yan Zhang, Doctor          Principal Investigator: Wei D Han, Doctor          Sub-Investigator: Xue C Lu, Doctor Less <<
NCT01417767 Myelodysplastic Syndromes Phase 2 Phase 3 Unknown September 2013 China, Shanghai ... More >> Shanghai 6th People's Hospital Not yet recruiting Shanghai, Shanghai, China, 200233 Contact: Xiao Li       lixiao3326@yahoo.com.cn    Principal Investigator: Xiao Li Less <<
NCT01685515 Sickle Cell Disease Phase 1 Completed - United States, Illinois ... More >> University of Illinois at Chicago Chicago, Illinois, United States, 60612 Less <<
NCT00561912 Renal Cell Carcinoma Phase 2 Terminated(Low accrual.) - United States, Texas ... More >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00561912 - Terminated(Low accrual.) - -
NCT02003573 Leukemia, Myeloid, Acute Phase 1 Terminated - United States, Connecticut ... More >> Boehringer Ingelheim Investigational Site New Haven, Connecticut, United States United States, Missouri Boehringer Ingelheim Investigational Site St. Louis, Missouri, United States United States, New York Boehringer Ingelheim Investigational Site Lake Success, New York, United States United States, Texas Boehringer Ingelheim Investigational Site Houston, Texas, United States Less <<
NCT00882102 - Completed - -
NCT00882102 Acute Myelogenous Leukemia ... More >> Myelodysplastic Syndrome Less << Phase 2 Completed - United States, Texas ... More >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03661307 Acute Myeloid Leukemia With FL... More >>T3/ITD Mutation Blasts More Than 10 Percent of Bone Marrow Nucleated Cells Blasts More Than 10 Percent of Peripheral Blood White Cells Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Recurrent Myelodysplastic Syndrome Less << Phase 1 Phase 2 Recruiting January 1, 2020 United States, Texas ... More >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Musa Yilmaz    713-745-9945       Principal Investigator: Musa Yilmaz Less <<
NCT02961101 Malignancies Multiple Phase 1 Phase 2 Recruiting May 2020 China, Beijing ... More >> Biotherapeutic Department of Chinese PLA General Hospital Recruiting Beijing, Beijing, China, 100853 Contact: Weidong Han, Doctor    +86-10-66937463    hanwdrsw@sina.com    Contact: Qingming Yang, Doctor    +86-10-55499341    yangqm@medmail.com.cn    Principal Investigator: Yang Liu, Doctor          Principal Investigator: Chunmeng Wang, Master          Principal Investigator: Wenying Zhang, Master          Principal Investigator: Meixia Chen, Doctor          Principal Investigator: Weidong Han, Doctor          Principal Investigator: Qingming Yang, Doctor          Principal Investigator: Qian Mei, Doctor          Principal Investigator: Jing Nie, Doctor          Sub-Investigator: Yan Zhang, Doctor          Sub-Investigator: Kaichao Feng, Doctor          Sub-Investigator: Jingdan Qiu, Doctor          Sub-Investigator: Hejin Jia, Doctor          Sub-Investigator: Xiang Li, Master          Sub-Investigator: Liang Dong, Master          Sub-Investigator: Lu Shi, Master Less <<
NCT00903760 - Completed - -
NCT00903760 Myelodysplastic Syndrome Phase 2 Completed - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00986804 Leukemia, Myeloid, Acute|Myelo... More >>dysplastic Syndromes Less << PHASE1 COMPLETED 2025-02-16 Washington University School o... More >>f Medicine, St. Louis, Missouri, 63110, United States Less <<
NCT00349596 Acute Lymphocytic Leukemia PHASE1 COMPLETED 2025-10-14 University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less <<
NCT00414310 Myelodysplastic Syndrome ... More >> Acute Myelogenous Leukemia Less << Phase 2 Completed - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00414310 - Completed - -
NCT03535753 NHL Phase 1 Recruiting November 1, 2020 China, Beijing ... More >> Peking university third hospital Recruiting Peking, Beijing, China, 010 Contact: Xinan Lu, Dr Less <<
NCT03113071 Acute Myeloid Leukemia ... More >> Myelodysplastic Syndromes Less << Phase 1 Phase 2 Recruiting January 2022 United States, Pennsylvania ... More >> Fox Chase Cancer Center Recruiting Philadelphia, Pennsylvania, United States, 19111 Contact: Philip Pancari, MD          Jeans Hospital Recruiting Philadelphia, Pennsylvania, United States, 19111 Contact: Philip Pancari, MD Less <<
NCT02159820 Primary Malignant Neoplasm of ... More >>Ovary FIGO Stages II to IV Less << Phase 2 Phase 3 Recruiting June 2024 China, Beijing ... More >> Chinese PLA General Hospital Recruiting Beijing, Beijing, China, 100853 Contact: Yan Zhang, Dr.    86-10-55499341    zhangyan@163.com    Principal Investigator: Yuanguang Meng, Professor Less <<
NCT02214407 MDS Phase 3 Recruiting December 2020 France ... More >> CHU La Réunion - Site nord Not yet recruiting Saint-Denis, La Réunion, France, 97400 Contact: Tahar Touahri, MD       tahar.touahri@chu-reunion.fr    Principal Investigator: Tahar Touahri, MD          CHU La Réunion-Site Sud Not yet recruiting Saint-Pierre, La Réunion, France, 97410 Contact: Patricia Zunic, MD       patricia.zunic@chu-reunion.fr    Principal Investigator: Patricia Zunic, MD          Chu Amiens Recruiting Amiens, France, 80054 Contact: Lavinia Merlusca, MD    0322455915    merlusca.lavinia@chu-amiens.fr    Principal Investigator: Lavinia Merlusca, MD          CHU d'Angers Recruiting Angers, France, 49 000 Contact: Mathilde Hunault    +33 2 41 35 44 75    MaHunault@chu-angers.fr    Principal Investigator: Mathilde Hunault, Professor          CH Victor Dupouy Not yet recruiting Argenteuil, France, 95107 Contact: Ahmad Al Jijakli, MD    +33134232339    ahmad.aljijakli@ch-argenteuil.fr    Principal Investigator: Ahmad Al Jijakli, MD          Ch Avignon Recruiting Avignon, France, 84000 Contact: Bohrane Slama, MD    0432753132    bslama@ch-avignon.fr    Principal Investigator: Bohrane Slama, MD          Centre Hospitalier de La Cote Basque Not yet recruiting Bayonne, France, 64100 Contact: Anne Banos, MD    033559443832    abanos@ch-cotebasque.fr    Principal Investigator: Anne Banos, MD          Hôpital Nord Franche-Comté Not yet recruiting Belfort, France, 90015 Contact: Marius Moldovan, MD    +33 3 84 98 23 17    marius.moldovan@hnfc.fr    Principal Investigator: Marius Moldovan, MD          Hôpital Avicenne Recruiting Bobigny, France, 93009 Contact: Thorsten Braun, MD    (0) 33 1 48 95 70 51    thorsten.braun@avc.aphp.fr    Principal Investigator: Thorsten Braun, MD          CHU de Brest - Hôpital Morvan Not yet recruiting Brest, France, 29609 Contact: Jean-Richard Eveillard, MD    33 2 98 22 33 33    jean-richard.eveillard@chu-brest.fr    Principal Investigator: Jean-Richard Eveillard, MD          CHU Côte de Nacre Recruiting Caen, France, 14033 Contact: Stéphane CHEZE, MD    0033231272360    cheze-s@chu-caen.fr    Principal Investigator: Stéphane CHEZE, MD          Hôpital privé Sévigné Recruiting Cesson-Sévigné, France, 35510 Contact: Benoît Bareau, MD    +33 2 23 21 05 50    benoit.bareau@gmail.com    Principal Investigator: Benoît Bareau, MD          CHU Estaing Recruiting Clermont-Ferrand, France, 63058 Contact: Benoit De RENZIS, MD    0334 73 75 00 65    bderenzis@chu-clermontferrand.fr    Principal Investigator: Benoit De RENZIS, MD          CH de Compiègne Not yet recruiting Compiègne, France, 60321 Contact: Sophie Dennetière, MD    +33 3 44 23 63 47    s.dennetiere@ch-compiegnenoyon.fr    Principal Investigator: Sophie Dennetière, MD          Centre Hospitalier Sud-Francilien Not yet recruiting Corbeil-Essonnes, France, 91106 Contact: Célia Salanoubat, MD    +33 1 60 90 31 78    celia.salanoubat@ch-sud-francilien.fr    Principal Investigator: Célia Salanoubat, MD          Centre Henri Mondor Recruiting Créteil, France, 94010 Contact: Andrea Toma, MD    0033149812057    andrea.toma@hmn.aphp.fr    Principal Investigator: Andrea Toma, MD          CHU Albert Michallon Recruiting Grenoble, France, 38043 Contact: Stéphane COURBY, MD    033 4 76 76 57 12    SCourby@chu-grenoble.fr    Principal Investigator: Stéphane COURBY, MD          Principal Investigator: Sophie Park, PHD          CH Le Mans Recruiting Le Mans, France, 72000 Contact: Kamel Laribi, MD    0243434361    klaribi@ch-lemans.fr    Principal Investigator: Kamel Laribi, MD          Clinique Victor Hugo Not yet recruiting Le Mans, France, 72000 Contact: Anne Parcelier, MD    +33 2 43 47 94 93    a.parcelier@i-l-c.fr    Principal Investigator: Anne Parcelier, MD          Hôpital Saint Vincent de Paul Not yet recruiting Lille, France, 59020 Contact: Laurent Pascal, MD, PHD    +33320874532    pascal.laurent@ghicl.net    Principal Investigator: Laurent Pascal, MD, PHD          CHRU de Limoges Recruiting Limoges, France, 87046 Contact: Marie-Pierre Gourin, MD    0033555056651    marie-pierre.gourin@chu-limoges.fr    Principal Investigator: Marie Pierre Gourin, MD          Centre Hospitalier Lyon Sud Recruiting Lyon, France, 69495 Contact: Eric WATTEL, PHD,MD    033 4 72 11 74 01    eric.wattel@chu-lyon.fr    Principal Investigator: Eric WATTEL, PHD,MD          Institut Paoli-Calmette Recruiting Marseille, France, 13009 Contact: Norbert VEY, PHD,MD    033 4 91 22 37 54    veyn@marseille.fnclcc.fr    Principal Investigator: Norbert VEY, PHD,MD          Centre Hospitalier de Meaux Not yet recruiting Meaux, France, 77100 Contact: Loïc Fouillard, MD    033164653876    l-fouillard@ch-meaux.fr    Principal Investigator: Loïc Fouillard, MD          Clinique Beausoleil Not yet recruiting Montpellier, France, 34000 Contact: Sophie Auger-Quittet, MD    +33467759999    s.auger-quittet@languedoc-mutualite.fr    Principal Investigator: Sophie Auger-Quittet, MD          Hôpital Saint Eloi Recruiting Montpellier, France, 34295 Contact: Robert Navarro, MD    +33467338362    r-navarro@chu-montpellier.fr    Principal Investigator: Robert Navarro, MD          Hopital de l'Hotel Dieu Recruiting Nantes, France, 44093 Contact: Pierre Peterlin, MD    +33 2 40 08 32 71    pierre.peterlin@chu-nantes.fr    Principal Investigator: Pierre Peterlin, MD          Hopital Archet I Not yet recruiting Nice, France, 06202 Contact: Laurence LEGROS, MD    00 33 4 92 03 58 44    legros.l@chu-nice.fr    Principal Investigator: Laurence LEGROS, MD          CHU de Nîmes Recruiting Nîmes, France, 30029 Contact: Stefan Wickenhauser, MD    +33 4 66 68 40 33    stefan.wickenhauser@chu-nimes.fr    Principal Investigator: Stefan Wickenhauser, MD          CHR d'Orléans Recruiting Orléans, France, 45067 Contact: Ali Arar, MD    +33238229546    ali.arar@chr-orleans.fr    Principal Investigator: Ali Arar, MD          Hopital St Louis T4 Recruiting Paris, France, 75475 Contact: Pierre Fenaux, PHD    0171207022    pierre.fenaux@sls.aphp.fr    Principal Investigator: Pierre Fenaux, PHD          Principal Investigator: ITZYKSON Raphael, MD          Centre Hospitalier Joffre Recruiting Perpignan, France, 66046 Contact: Laurence Sanhes, MD    00 33 468616448    laurence.sanhes@ch-perpignan.fr    Principal Investigator: Laurence Sanhes, MD          CHU de Haut-Lévèque Not yet recruiting Pessac, France, 33604 Contact: Sophie Dimicoli-Salazar, MD    033557656511    sophie.dimicoli-salazar@chu-bordeaux.fr    Principal Investigator: Sophie Dimicoli-Salazar, MD          CHU Poitiers Recruiting Poitiers, France, 86021 Contact: Jose Miguel Torregrosa Diaz, MD    +33548444444    jose-miguel.torregrosa-diaz@chu-poitiers.fr    Principal Investigator: Jose Miguel Torregrosa Diaz, MD          CH René Dubos Not yet recruiting Pontoise, France, 95000 Contact: Riad Benramdane, MD    +33156831442    benramdaner@yahoo.fr    Principal Investigator: Riad Benramdane, MD          CH Annecy Genevois Not yet recruiting Pringy, France, 74374 Contact: Pascale Cony-Makhoul, MD    +33 4 50 63 64 31    pconymakhoul@ch-annecygenevois.fr    Principal Investigator: Pascale Cony-Makhoul, MD          CHU de Reims Not yet recruiting Reims, France, 51092 Contact: Chantal HIMBERLIN, MD    003326783644    chimberlin@chu-reims.fr    Principal Investigator: Chantal HIMBERLIN, MD          CHU Pontchaillou Recruiting Rennes, France, 35033 Contact: Stanislas Nimubona, MD    33299289521    stanislas.nimubona@chu-rennes.fr    Principal Investigator: Stanislas Nimubona, MD          Centre Henri Bequerel Recruiting Rouen, France, 76038 Contact: Aspasia STAMATOULLAS, MD    00 33 2 32 08 22 88    aspasia.stamatoullas@chb.unicancer.fr    Principal Investigator: Aspasia STAMATOULLAS, MD          Hôpital Hautepierre Not yet recruiting Strasbourg, France, 67098 Contact: Shanti Natarajan-Ame, MD    +33388121670    shanti.ame@chru-strasbourg.fr    Principal Investigator: Shanti Natarajan-Ame, MD          IUCT Oncopole - Département d'hématologie Not yet recruiting Toulouse, France, 31059 Contact: Christian RECHER, MD, PHD    05 61 77 20 78    recher.christian@iuct-oncopole.fr    Principal Investigator: Christian RECHER, MD          Iuct Oncopole Recruiting Toulouse, France, 31059 Contact: Odile BEYNE-RAUZY, MD, PHD    +33(0)5 31 15 62 64    beynerauzy.odile@iuct-oncopole.fr    Principal Investigator: Odile Beyne-Rauzy, PHD          CH Valence Not yet recruiting Valence, France, 26953 Contact: Jixing Liu, MD    +33475757566    jliu@ch-valence.fr    Principal Investigator: Jixing Liu, MD          CHU Brabois Not yet recruiting Vandœuvre-lès-Nancy, France, 54511 Contact: Agnès GUERCI-BRESLER, MD    0033383153281    a.guerci@chu-nancy.fr    Principal Investigator: Agnès GUERCI-BRESLER, MD          Institut gustave Roussy Not yet recruiting Villejuif, France, 94805 Contact: Eric Solary, MD    +33142114507    eric.solary@igr.fr    Principal Investigator: ERIC SOLARY, MD Less <<
NCT03041688 Acute Myeloid Leukemia ... More >> Blasts 5 Percent or More of Bone Marrow Nucleated Cells Recurrent Adult Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia TP53 wt Allele Untreated Adult Acute Myeloid Leukemia Less << Phase 1 Recruiting October 31, 2019 United States, California ... More >> City of Hope Comprehensive Cancer Center Recruiting Duarte, California, United States, 91010 Contact: Site Public Contact    800-826-4673    becomingapatient@coh.org    Principal Investigator: Samer K. Khaled          Los Angeles County-USC Medical Center Recruiting Los Angeles, California, United States, 90033 Contact: Site Public Contact    323-865-0451       Principal Investigator: Kevin R. Kelly          USC / Norris Comprehensive Cancer Center Recruiting Los Angeles, California, United States, 90033 Contact: Site Public Contact    323-865-0451       Principal Investigator: Kevin R. Kelly          Keck Medical Center of USC Pasadena Recruiting Pasadena, California, United States, 91105 Contact: Site Public Contact    323-865-0451       Principal Investigator: Kevin R. Kelly          University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Site Public Contact    916-734-3089       Principal Investigator: Brian A. Jonas          United States, Kentucky University of Kentucky/Markey Cancer Center Recruiting Lexington, Kentucky, United States, 40536 Contact: Site Public Contact    859-257-3379       Principal Investigator: Reshma Ramlal          United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Recruiting Baltimore, Maryland, United States, 21287 Contact: Site Public Contact    410-955-8804    jhcccro@jhmi.edu    Principal Investigator: Jonathan A. Webster          United States, Massachusetts Massachusetts General Hospital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Site Public Contact    877-726-5130       Principal Investigator: Myrna R. Nahas          Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Site Public Contact    888-823-5923    ctsucontact@westat.com    Principal Investigator: Myrna R. Nahas          Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact    617-667-9925       Principal Investigator: Myrna R. Nahas          Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact    877-442-3324       Principal Investigator: Myrna R. Nahas          United States, Ohio Ohio State University Comprehensive Cancer Center Active, not recruiting Columbus, Ohio, United States, 43210 Less <<
NCT00477386 Ovarian Cancer Phase 1 Phase 2 Completed - United States, Indiana ... More >> Indiana University Cancer Center Indianapolis, Indiana, United States, 46202 Less <<
NCT03021395 AML PHASE1|PHASE2 SUSPENDED 2025-12-22 Institute of Hematology & Bloo... More >>d Diseases Hospital, Tianjin, Tianjin, China Less <<
NCT03063203 Acute Myeloid Leukemia ... More >> Acute Myeloid Leukemia, Relapsed, Adult Less << Phase 2 Recruiting July 31, 2025 United States, Illinois ... More >> University of Chicago Withdrawn Chicago, Illinois, United States, 60637 United States, Iowa University of Iowa Not yet recruiting Iowa City, Iowa, United States, 52242 Contact: Carlos Vigil, M.D.       carlos-vigil@uiowa.edu    Principal Investigator: Carlos Vigil, M.D.          United States, Massachusetts Massachusetts General Hospital Withdrawn Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Withdrawn Boston, Massachusetts, United States, 02215 United States, Missouri Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: John Welch, M.D., Ph.D.    314-362-2626    jwelch@wustl.edu    Principal Investigator: John Welch, M.D., Ph.D.          United States, Texas The University of Texas MD Anderson Cancer Center Withdrawn Houston, Texas, United States, 77030 United States, Washington Fred Hutchinson Cancer Research Center Not yet recruiting Seattle, Washington, United States, 98109 Contact: Elihu Estey, M.D.    206-288-7176    eestey@u.washington.edu    Principal Investigator: Elihu Estey, M.D. Less <<
NCT00477386 - Completed - -
NCT01130662 Acute Myeloid Leukemia Phase 1 Completed - United States, Kansas ... More >> University of Kansas Medical Center, Westwood Campus Kansas City, Kansas, United States, 66205 Less <<
NCT03709550 Castration Levels of Testoster... More >>one Castration-Resistant Prostate Carcinoma Metastatic Prostate Carcinoma in the Soft Tissue Prostate Carcinoma Metastatic in the Bone PSA Level Greater Than or Equal to Two PSA Progression Stage IV Prostate Cancer AJCC v8 Stage IVA Prostate Cancer AJCC v8 Stage IVB Prostate Cancer AJCC v8 Less << Phase 1 Phase 2 Not yet recruiting August 31, 2020 United States, New York ... More >> Roswell Park Cancer Institute Not yet recruiting Buffalo, New York, United States, 14263 Contact: Gurkamal S. Chatta    716-845-3117    Gurkamal.Chatta@roswellpark.org    Principal Investigator: Gurkamal S. Chatta Less <<
NCT01133886 Acute Myeloid Leukemia|Chronic... More >> Myelomonocytic Leukemia|Myelodysplastic Syndrome Less << PHASE2 UNKNOWN 2025-09-13 King's College Hospital NHS Fo... More >>undation Trust, London, SE5 9RS, United Kingdom Less <<
NCT01628471 Non Small Cell Lung Cancer Phase 1 Phase 2 Completed - Canada, Quebec ... More >> Hôpital Notre Dame du CHUM Montreal, Quebec, Canada, H2L 4M1 Less <<
NCT02996474 Relapsed Acute Myeloid Leukemi... More >>a Less << Phase 1 Phase 2 Active, not recruiting July 1, 2019 United States, Maryland ... More >> National Institutes of Health Clinical Center Bethesda, Maryland, United States, 20892 Less <<
NCT03250962 Hodgkin Lymphoma Phase 1 Phase 2 Recruiting March 21, 2020 China, Beijing ... More >> Biotherapeutic Department of Chinese PLA General Hospital Recruiting Beijing, Beijing, China, 100853 Contact: Weidong Han, Doctor    +86-10-66937463    hanwdrsw@sina.com    Contact: Qingming Yang, Doctor    +86-10-55499341    yangqm@medmail.com.cn    Principal Investigator: Yang Liu, Doctor          Principal Investigator: Chunmeng Wang, Master          Principal Investigator: Wenying Zhang, Master          Principal Investigator: Meixia Chen, Doctor          Principal Investigator: Weidong Han, Doctor          Principal Investigator: Qingming Yang, Doctor          Principal Investigator: Qian Mei, Doctor          Principal Investigator: Jing Nie, Doctor          Sub-Investigator: Yan Zhang, Doctor          Sub-Investigator: Kaichao Feng, Doctor          Sub-Investigator: Jingdan Qiu, Doctor          Sub-Investigator: Hejin Jia, Doctor          Sub-Investigator: Xiang Li, Master          Sub-Investigator: Liang Dong, Master          Sub-Investigator: Lu Shi, Master Less <<
NCT03558412 T-lymphoblastic Lymphoma Phase 4 Recruiting June 1, 2020 China, Henan ... More >> Oncology Department of The First Affiliated Hospital of Zhengzhou University Recruiting Zhengzhou, Henan, China, 450052 Contact: Mingzhi Zhang, Pro,Dr    13838565629    mingzhi_zhang@126.com    Contact: Mingzhi Zhang, Pro,Drc    13838565629    mingzhi_zhang@126.com Less <<
NCT02878785 Acute Myeloid Leukemia Phase 1 Phase 2 Recruiting December 2022 United States, Maryland ... More >> University of Maryland Greenebaum Comprehensive Cancer Center Recruiting Baltimore, Maryland, United States, 21201 Contact: Sunita Philip, MPH, CCRP    410-328-8199    sphilip1@umm.edu    Contact: Gary Saum    410-328-1180    gary.saum@umm.edu    Principal Investigator: Maria Baer, MD Less <<
NCT00866073 Acute Myeloid Leukemia Phase 2 Completed - Germany ... More >> Medizinische Hochschule Hannover Hannover, Niedersachsen, Germany, 30625 Klinikum der Technischen Universität Aachen Aachen, Germany Universitätsklinikum Düsseldorf Düsseldorf, Germany Katholisches Krankenhaus Hagen Hagen, Germany Klinikum Lüdenscheid Luedenscheid, Germany Universitätsklinikum Ulm Ulm, Germany Klinikum Villingen-Schwenningen Villingen-Schwenningen, Germany Netherlands Leyenburg Hospital The Hague, Netherlands Less <<
NCT02013102 Myelodysplastic Syndrome Phase 4 Unknown December 2015 China, Tianjin ... More >> Tianjin Medical University General Hospital Recruiting Tianjin, Tianjin, China, 300052 Contact: LIU HUI, MD          Principal Investigator: Shao Zonghong, MD Less <<
NCT01098084 Chronic Myelomonocytic Leukemi... More >>a Less << PHASE2 COMPLETED 2025-06-09 CHU de Bicêtre, Le Kremlin-Bic... More >>être, Ile de France, 94275, France|CHU d'Amiens, Amiens, 80054, France|CH Angers, Angers, 49 000, France|H?pital Avignon, Avignon, 84000, France|Hopital de la Cote Basque, Bayonne, 64100, France|H?pital Avicenne, Bobigny, 93009, France|CHU Haut-Lévèque, Bordeaux, 33604, France|H?pital Boulogne Sur Mer, Boulogne Sur Mer, 62321, France|Hopital d'Instruction des Armées Percy, Clamart, 92140, France|CHU de, Clermont Ferrand, 63058, France|Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, 91106, France|Hopital Henri Mondor, Creteil, 94000, France|CHU de Dijon, Dijon, 21034, France|H?pital Versailles, Le Chesnay, 78157, France|Centre Hospitalier du Mans, Le Mans cedex, 72037, France|Institut Paoli Calmettes, Marseille, 13009, France|CHU de nantes, Nantes, 44093, France|H?pital Archet1, Nice, 06202, France|CHU Caremeau, Nimes, 30029, France|CHR La Source orléans, Orléans, 45067, France|H?pital Saint-Antoine., Paris-Cedex 12, 75571, France|Hopital Cochin, Paris, 75014, France|Hopital Necker, Paris, 75015, France|Hopital Hotel Dieu, Paris, 75181, France|Hoiptal St Louis, Paris, 75475, France|Centre Hospitalier Joffre, Perpignan, 66046, France|CHU de Reims, Reims, 51092, France|Centre Henri Becquerel, Rouen, 76038, France|Hematology Dpt, Hopital Purpan, Toulouse, 40031, France|CHU Bretoneau, Tours, 37044, France|Institut gustave Roussy, Villejuif, 94805, France Less <<
NCT02076191 Myeloproliferative Neoplasms Phase 1 Phase 2 Active, not recruiting December 2018 United States, Missouri ... More >> Washington University of St. Louis Saint Louis, Missouri, United States, 63110 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Columbia University Medical Center New York, New York, United States, 10032 Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Wake Forest University Baptist Medical Center Winston-Salem, North Carolina, United States, 27157 United States, Ohio Cleveland Clinic Taussig Cancer Center Institute Cleveland, Ohio, United States, 44195 United States, Pennsylvania University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT00760084 Acute Myelogenous Leukemia|Mye... More >>lodysplastic Syndrome Less << PHASE2 COMPLETED 2025-02-08 Washington University School o... More >>f Medicine, St. Louis, Missouri, 63110, United States Less <<
NCT01882660 Colon Cancer TERMINATED 2025-01-18 Academic Medical Center, Amste... More >>rdam, 1105 AZ, Netherlands Less <<
NCT01333449 Myelodysplastic Syndrome PHASE2 TERMINATED 2025-08-13 Singapore General Hospital, Si... More >>ngapore, 169608, Singapore Less <<
NCT03282825 Advanced Breast Cancer Phase 1 Active, not recruiting May 2018 Korea, Republic of ... More >> Yonsei University Health System, Severance Hospital Seoul, Korea, Republic of, 03722 Less <<
NCT02010645 Leukemia Phase 2 Active, not recruiting March 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02847000 Metastatic Pancreatic Adenocar... More >>cinoma Less << Early Phase 1 Active, not recruiting December 2018 United States, Ohio ... More >> University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106 Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 Less <<
NCT00744757 Myelodysplastic Syndrome PHASE2 COMPLETED 2025-08-12 Changhua, Taiwan|Kaohsiung, Ta... More >>iwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Tau-Yuan County 333, Taiwan Less <<
NCT01149408 Acute Myeloid Leukemia ... More >> AML Less << Phase 1 Completed - United States, Utah ... More >> University of Utah, Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 Less <<
NCT03395873 Acute Myeloid Leukemia Phase 1 Recruiting December 31, 2020 United States, Pennsylvania ... More >> Penn State Cancer Institute Recruiting Hershey, Pennsylvania, United States, 17033 Contact: Clinical Research Nurse    717-531-7309    hzheng@pennstatehealth.psu.edu    Contact: Michelle Knapp, RN    717-531-0003    mknapp1@pennstatehealth.psu.edu    Principal Investigator: Hong Zheng, MD Less <<
NCT02890329 Acute Myeloid Leukemia ... More >> Blasts 5 Percent or More of Bone Marrow Nucleated Cells Hematopoietic Cell Transplantation Recipient Myelodysplastic Syndrome Previously Treated Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes Recurrent Adult Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia Less << Phase 1 Recruiting July 1, 2020 United States, California ... More >> City of Hope Comprehensive Cancer Center Recruiting Duarte, California, United States, 91010 Contact: Site Public Contact    800-826-4673    becomingapatient@coh.org    Principal Investigator: Samer K. Khaled          University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Site Public Contact    916-734-3089       Principal Investigator: Brian A. Jonas          United States, Florida Moffitt Cancer Center Active, not recruiting Tampa, Florida, United States, 33612 United States, Massachusetts Massachusetts General Hospital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Site Public Contact    877-726-5130       Principal Investigator: Jacqueline S. Garcia          Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Site Public Contact    888-823-5923    ctsucontact@westat.com    Principal Investigator: Jacqueline S. Garcia          Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact    617-667-9925       Principal Investigator: Jacqueline S. Garcia          Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact    877-442-3324       Principal Investigator: Jacqueline S. Garcia          United States, Ohio Case Western Reserve University Recruiting Cleveland, Ohio, United States, 44106 Contact: Site Public Contact    800-641-2422    CTUReferral@UHhospitals.org    Principal Investigator: Benjamin K. Tomlinson          United States, Virginia University of Virginia Cancer Center Recruiting Charlottesville, Virginia, United States, 22908 Contact: Site Public Contact    434-243-6303    PAS9E@virginia.edu    Principal Investigator: Michael K. Keng Less <<
NCT01498445 Leukemia Phase 1 Phase 2 Active, not recruiting June 2021 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02472145 Leukemia, Myeloid, Acute Phase 3 Completed - -
NCT00760084 Acute Myelogenous Leukemia|Mye... More >>lodysplastic Syndrome Less << PHASE2 COMPLETED 2025-02-08 Washington University School o... More >>f Medicine, St. Louis, Missouri, 63110, United States Less <<
NCT03663751 Response Rate PHASE2 COMPLETED 2021-03-01 Blood & Marrow Transplantation... More >> Center, RuiJin Hospital, Shanghai, Shanghai, 200025, China Less <<
NCT01786343 Leukemia PHASE2 COMPLETED 2019-05-06 University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less <<
NCT03579082 Diffuse Large B Cell Lymphoma PHASE4 UNKNOWN 2019-12-01 Oncology Department of The Fir... More >>st Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China Less <<
NCT03066648 Leukemia Leuk... More >>emia, Myeloid Leukemia, Myeloid, Acute Myelodysplastic Syndromes Preleukemia Bone Marrow Diseases Hematologic Diseases Less << Phase 1 Recruiting April 1, 2020 United States, Massachusetts ... More >> Novartis Investigative Site Recruiting Boston, Massachusetts, United States, 02114 Contact: Meghan Burke    617-726-5131    Mburke19@partners.org    Principal Investigator: Andrew M. Brunner          United States, Oregon Novartis Investigative Site Recruiting Portland, Oregon, United States, 97239 United States, Texas Novartis Investigative Site Recruiting Houston, Texas, United States, 77030 Australia, Victoria Novartis Investigative Site Recruiting Melbourne, Victoria, Australia, 3004 Finland Novartis Investigative Site Recruiting Helsinki, Finland, FIN-00290 France Novartis Investigative Site Recruiting Marseille, France, 13273 Germany Novartis Investigative Site Recruiting Jena, Germany, 07740 Netherlands Novartis Investigative Site Recruiting Amsterdam, Netherlands, 1081 HV Spain Novartis Investigative Site Recruiting Barcelona, Catalunya, Spain, 08036 United Kingdom Novartis Investigative Site Recruiting Cardiff, United Kingdom, CF4 4XN Less <<
NCT00744757 Myelodysplastic Syndrome PHASE2 COMPLETED 2025-08-12 Changhua, Taiwan|Kaohsiung, Ta... More >>iwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Tau-Yuan County 333, Taiwan Less <<
NCT02234037 Leukemia Phase 1 Terminated(Slow accrual) - United States, Georgia ... More >> Winship Cancer Institute of Emory University Atlanta, Georgia, United States, 30322 Less <<
NCT01687400 Leukemia, Myeloid, Acute ... More >> Myelodysplastic Syndromes Less << Phase 2 Completed - United States, Missouri ... More >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 Less <<
NCT02698124 Acute Myeloid Leukemia|Elderly... More >>|Intensive Chemotherapy Unfit Less << UNKNOWN 2025-12-22 Ulsan University Hospital, Uls... More >>an, 682714, Korea, Republic of Less <<
NCT02959164 Pancreatic Ductal Adenocarcino... More >>ma Sarcoma Less << Phase 1 Recruiting July 2020 United States, Iowa ... More >> University of Iowa Hospitals and Clinics Recruiting Iowa City, Iowa, United States, 52242 Contact: Varun Monga, MD    319-384-9497    varun-monga@uiowa.edu Less <<
NCT01251627 Chronic Myelomonocytic Leukemi... More >>a Less << PHASE2 COMPLETED 2025-06-18 Ematologia, Ospedale SS Antoni... More >>o e Biagio e Cesare Arrigo, Alessandria, 15121, Italy|AOU Ospedali Riuniti di Ancona, Ancona, 60131, Italy|Ematologia AOU Policlinico di Bari, Bari, 70124, Italy|Istituto di Ematologia e Oncologia Medica, Policlinico S.Orsola, Bologna, 40100, Italy|Ematologia - Spedali Civili, Brescia, 25100, Italy|Ematologia- Ospedale Businco, Cagliari, 09121, Italy|Centro di ricerca e formazione ad alta tecnologia nelle Scienze, Università Cattolica, Campobasso, 86100, Italy|Cattedra di Ematologia Policlino Careggi, Firenze, 50134, Italy|Dipartimento Emato-Oncologia AOU San Martino Genova, Genova, 16132, Italy|Fondazione IRCCS Caà Granda-Ospedale Maggiore policlinico, Milano, 20121, Italy|Divisione di Ematologia, Ospedale S.Gerardo di Monza, Monza, 20052, Italy|Divisione di Ematologia, Università Avogadro, Novara, 28100, Italy|Medicina interna II Divisione di Ematologia Ospedale S.Luigi Gonzaga, Orbassano, 10043, Italy|Azienda Ospedaliera di Padova, Padova, 35128, Italy|Ospedale S.Maria della Misericordia, Perugia, 06122, Italy|AOU San Salvatore, Pesaro, 61122, Italy|AO Bianchi Melacrino Morelli, Reggio Calabria, 89125, Italy|IRCCS Centri di riferimento oncologico, Rionero in Vulture, 85028, Italy|SC Ematologia AOU S.Andrea, Roma, 00183, Italy|Ematologia 2-Ospedale S.Giovanni Battista, Torino, 10126, Italy|U.O.Ematologia 2, Torino, 10126, Italy Less <<
NCT02141477 Leukemia Phase 1 Terminated(Slow Accrual-2 pati... More >>ents were registered Phase I and none in Phase II) Less << - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02499861 Cancer Phase 1 Phase 2 Completed - Canada, Quebec ... More >> St. Justine's Hospital Montreal, Quebec, Canada, H3T 1C5 Less <<
NCT01687400 - Completed - -
NCT01633099 Untreated Adult Acute Myeloid ... More >>Leukemia|Effect of Drugs|Drug Safety Less << PHASE3 UNKNOWN 2025-07-16 -
NCT01568333 Immune Thrombocytopenia PHASE2 COMPLETED 2025-08-18 Shandong University Qilu hospi... More >>tal, Jinan, Shandong, 250012, China Less <<
NCT01893320 Leukemia Phase 1 Phase 2 Active, not recruiting July 2020 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02252107 Acute Myeloid Leukemia (AML) Phase 2 Active, not recruiting October 2019 Belgium ... More >> University of Liège Liège, Belgium Netherlands University Medical Center Groningen (UMCG) Groningen, Netherlands Radboud university medical center Nijmegen, Netherlands, 6500 HB Less <<
NCT01277484 Myelodysplastic Syndrome|Acute... More >> Myeloid Leukemia Less << PHASE1 UNKNOWN 2025-12-15 Seoul St. Mary's Hospital, Seo... More >>ul, 137-701, Korea, Republic of Less <<
NCT02264873 Leukemia, Lymphoblastic, Acute... More >>|Leukemia, Myeloid Acute|Hematopoetic Myelodysplasia Less << PHASE1 COMPLETED 2018-09-18 UF Health Shands Hospital, Gai... More >>nesville, Florida, 32610, United States Less <<
NCT03080766 Acute Myeloid Leukemia|Complex... More >> Karyotype Less << PHASE2 UNKNOWN 2021-12-28 The University of Hong Kong, H... More >>ong Kong, Hong Kong Less <<
NCT03404193 Other Diseases of Blood and Bl... More >>ood-forming Organs Acute Myeloid Leukemia Myelodysplastic Syndrome Less << Phase 2 Recruiting December 2020 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact       mkonople@mdanderson.org Less <<
NCT02316028 Liver Metastasis|Colorectal Ca... More >>ncer Less << PHASE1|PHASE2 COMPLETED 2025-07-17 UZ Brussel, Jette, Brabant, 10... More >>90, Belgium|UZ Brussel, Brussels, 1090, Belgium Less <<
NCT03045510 Myelodysplastic Syndromes Phase 2 Recruiting July 30, 2020 China, Shandong ... More >> Qilu hospital, Shandong University Recruiting Jinan, Shandong, China, 250012 Contact: Ming Hou       houming@medmail.com.cn    Principal Investigator: Ming Hou          Shandong University Qilu Hospital Recruiting Jinan, Shandong, China, 250012 Contact: Ming Lv          Principal Investigator: Ming Hou, Dr Less <<
NCT03445858 Childhood Solid Tumor ... More >> Childhood Lymphoma Relapsed Cancer Refractory Cancer Adult Solid Tumor Adult Lymphoma Less << Early Phase 1 Recruiting May 12, 2022 United States, Ohio ... More >> Cincinnati Children's Hospital Medical Center Recruiting Cincinnati, Ohio, United States, 45229 Contact: Laura Fossett    513-636-2799    cancer@cchmc.org Less <<
NCT03306264 Myelodysplastic Syndromes ... More >> Chronic Myelomonocytic Leukemia Less << Phase 3 Recruiting June 30, 2019 -
NCT02665065 Acute Myeloid Leukemia ... More >> Leukemia, Acute Myeloid Myeloid Leukemia, Acute Leukemia, Myeloid, Acute Acute Myelogenous Leukemia Leukemia, Acute Myelogenous Myelogenous Leukemia, Acute Less << Phase 3 Recruiting June 2020 United States, Arizona ... More >> Banner MD Anderson Cancer Center Recruiting Gilbert, Arizona, United States United States, Connecticut Yale Cancer Center Recruiting New Haven, Connecticut, United States United States, Florida Mayo Clinic Recruiting Jacksonville, Florida, United States United States, Illinois Loyola University Medical Center Recruiting Maywood, Illinois, United States United States, Kansas The University of Kansas Cancer Center Recruiting Westwood, Kansas, United States United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States United States, Missouri Washington University School of Medicine Recruiting Saint Louis, Missouri, United States United States, Nebraska University of Nebraska Medical Center Recruiting Omaha, Nebraska, United States United States, New York Roswell Park Cancer Institute Recruiting Buffalo, New York, United States Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States Stony Brook University Recruiting Stony Brook, New York, United States United States, Ohio University Hospital of Cleveland Seidman Cancer Center Recruiting Cleveland, Ohio, United States The Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States United States, Texas Baylor Charles A. Sammons Cancer Center Recruiting Dallas, Texas, United States MD Anderson Cancer Center Recruiting Houston, Texas, United States United States, Washington Fred Hutchinson Cancer Research Center Recruiting Seattle, Washington, United States United States, Wisconsin Medical College of Wisconsin Recruiting Milwaukee, Wisconsin, United States Canada, Ontario University of Ottawa Recruiting Ottawa, Ontario, Canada Less <<
NCT03662087 Minimal Residual Disease,Acute... More >> Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell Transplantation Less << Phase 2 Phase 3 Recruiting October 2022 China, Guangdong ... More >> Department of Hematology,Nanfang Hospital, Southern Medical University Recruiting Guangzhou, Guangdong, China, 510515 Contact: Hua Jin    +86-020-61641613    499509173@qq.com Less <<
NCT02788201 Urothelial Carcinoma ... More >> Bladder Cancer Urinary Bladder Neoplasms Less << Phase 2 Recruiting July 1, 2020 United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    888-624-1937 Less <<
NCT01258868 Mesolthelioma ... More >> Esophageal Cancer Lung Cancer Thoracic Sarcomas Thymoma Less << Phase 1 Terminated - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT01902329 Acute Myelogenous Leukemia ... More >> Acute Myeloid Leukemia Acute Promyelocytic Leukemia Less << Phase 1 Completed - United States, Alabama ... More >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, California City of Hope National Medical Center Duarte, California, United States, 91010-3000 United States, Florida H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States, 33612 United States, Georgia Winship Cancer Institute / Emory University School of Medicine Atlanta, Georgia, United States, 30322 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Michigan University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 United States, New Jersey Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10021 United States, Ohio Cleveland Clinic, The Cleveland, Ohio, United States, 44195 United States, Texas Charles A. Sammons Cancer Center / Baylor University Medical Center Dallas, Texas, United States, 75246 MD Anderson Cancer Center / University of Texas Houston, Texas, United States, 77030-4095 United States, Utah University of Utah Salt Lake City, Utah, United States, 84112 United States, Washington Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109-1024 Less <<
NCT02228525 Myelodysplastic Syndromes Phase 2 Active, not recruiting August 2019 United States, New York ... More >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT03236857 Malignancies ... More >>Acute Lymphoblastic Leukemia (ALL) Acute Myeloid Leukemia (AML) Non-Hodgkin's Lymphoma Neuroblastoma Less << Phase 1 Recruiting April 7, 2022 -
NCT03383575 Myelodysplastic Syndrome Phase 2 Recruiting January 2022 United States, Florida ... More >> Moffitt Cancer Center Recruiting Tampa, Florida, United States, 33612 Contact: Rami Komrokji, MD          United States, Maryland John Hopkins Recruiting Baltimore, Maryland, United States, 21218 Contact: Amy DeZern, MD          United States, Massachusetts Dana Farber Recruiting Boston, Massachusetts, United States, 02215 Contact: David Steensma, MD          United States, New York Weill Cornell Medicin Recruiting New York, New York, United States, 10065 Contact: Gail Roboz, MD          United States, Ohio Cleveland Clinic Recruiting Cleveland, Ohio, United States, 44195 Contact: Mikkael Sekeres, MD          United States, Texas University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Clinical Research Operations       cdinardo@mdanderson.org Less <<
NCT03642236 FLT3-ITD Mutation ... More >> Acute Myeloid Leukemia Brutons Tyrosine Kinase Less << Phase 2 Phase 3 Enrolling by invitation September 2023 China, Guangdong ... More >> Department of Hematology,Nanfang Hospital, Southern Medical University Guangzhou, Guangdong, China, 510515 Less <<
NCT00000623 - Completed - United States, California ... More >> Children's Hospital Oakland Oakland, California, United States, 94609 United States, Massachusetts Children's Hospital Boston, Massachusetts, United States, 02115 United States, New York Weill Medical College of Cornell University New York, New York, United States, 10021 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 Canada, Ontario Toronto General Hospital Toronto, Ontario, Canada, M5G 2C4 Less <<
NCT00903422 Myelodysplastic Syndrome Phase 1 Completed - -
NCT03229746 Immune Thrombocytopenia Phase 4 Completed - Egypt ... More >> Assiut university hospital Assiut, Egypt Less <<
NCT02684162 Leukemia Myel... More >>oproliferative Diseases Less << Phase 2 Recruiting June 2021 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Less <<
NCT00459524 - Completed - United States, Texas ... More >> U.T.M.D. Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01286038 Myelodysplastic Syndrome (MDS)... More >> Thrombocytopenia Less << Phase 1 Phase 2 Active, not recruiting April 2020 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Less <<
NCT02937662 Acute Myeloid Leukemia Phase 2 Recruiting December 2018 China ... More >> Institute of Hematology & Blood Diseases Hospital Recruiting Tianjin, China Contact: lijun Liu Less <<
NCT01814826 Acute Myelogenous Leukemia Phase 1 Completed - United States, Alabama ... More >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, California Stanford University Stanford, California, United States, 94305-5826 United States, Colorado Hospital Corporation of America-HealthOne, LLC Denver, Colorado, United States, 80218 United States, Florida Mayo Clinic - Jacksonville, FL Jacksonville, Florida, United States, 32224 University of Miami School of Medicine Miami, Florida, United States, 33136 United States, North Carolina UNC-Chapel Hill School of Medicine Chapel Hill, North Carolina, United States, 27599 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United States, Texas Methodist Hospital San Antonio, Texas, United States, 78229 Less <<
NCT02907359 Myelodysplastic Syndromes ... More >> Leukemia, Myelomonocytic, Chronic Less << Phase 3 Recruiting December 2019 -
NCT03013998 Previously Untreated Acute Mye... More >>loid Leukemia Less << Phase 1 Phase 2 Recruiting December 2021 United States, Arizona ... More >> Mayo Clinic Arizona Recruiting Phoenix, Arizona, United States, 85054 Principal Investigator: Lisa Sproat, MD          United States, California UCLA Ronald Reagan Medical Center Recruiting Los Angeles, California, United States, 90095 Principal Investigator: Gary Schiller, MD          University of California, San Francisco Recruiting San Francisco, California, United States, 94143 Principal Investigator: Gabriel Mannis, MD          United States, Colorado University of Colorado Recruiting Denver, Colorado, United States, 80203 Principal Investigator: Dan Pollyea, MD          United States, Florida Mayo Clinic Florida Recruiting Jacksonville, Florida, United States, 32224 Principal Investigator: James Foran, MD          United States, Georgia Emory University Recruiting Atlanta, Georgia, United States, 30308 Principal Investigator: William Blum, MD          United States, Illinois University of Chicago Recruiting Chicago, Illinois, United States, 60637 Principal Investigator: Wendy Stock, MD          United States, Maryland University of Maryland Medical Center Recruiting Baltimore, Maryland, United States, 21201 Principal Investigator: Maria Baer, MD          United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Principal Investigator: Eytan M Stein, MD          United States, Ohio Ohio State University Recruiting Columbus, Ohio, United States, 43210 Principal Investigator: John C Byrd, MD          Principal Investigator: Alice Mims, MD          Principal Investigator: Alison R Walker, MD, MPH          United States, Oregon Oregon Health & Science University Recruiting Portland, Oregon, United States, 97239 Principal Investigator: Uma Borate, MD          United States, Texas University of Texas Southwestern Recruiting Dallas, Texas, United States, 75390 Principal Investigator: Prapti Patel, MD          United States, Utah Huntsman Cancer Institute, University of Utah Recruiting Salt Lake City, Utah, United States, 84112 Principal Investigator: Michael Deininger, MD, PhD Less <<
NCT02363491 Myelodysplastic Syndrome Phase 1 Phase 2 Active, not recruiting April 2019 United States, Florida ... More >> Research Site Tampa, Florida, United States, 33613 United States, New York Research Site Bronx, New York, United States, 10467 Research Site New York, New York, United States, 10021 United States, Texas Research Site Houston, Texas, United States, 77030 Less <<
NCT02293993 Acute Myeloid Leukemia Phase 1 Active, not recruiting December 2019 Japan ... More >> kinki Region Kyoto, Japan Kanto Region, Japan Kyusyu Region, Japan Less <<
NCT00542828 Myelodysplastic Syndrome (MDS) Phase 2 Terminated(Study terminated du... More >>e to slow enrollment.) Less << - France ... More >> Hopital Avicenne/University Paris, France, 93009 Germany St. Johannes-Hospital Duisburg Duisburg, Germany, 47166 Medizinische Hochschule Hannover Hannover, Germany, 30625 Netherlands UMC St Radboud Centraal Nijmegen, Netherlands, 6525 GA United Kingdom Royal Bournemouth Hospital Bournemouth, England, United Kingdom, BH7 7DW St. James Hospital Leeds, England, United Kingdom, LS9 7TF King's College Hospital London, England, United Kingdom, SE5 9RS Less <<
NCT01261312 MDS CMML ... More >> AML Less << Phase 1 Phase 2 Completed - United States, Arizona ... More >> Mayo Clinic Scottsdale, Arizona, United States, 85259 United States, California University of Southern California Los Angeles, California, United States, 90033 United States, Connecticut Yale University New Haven, Connecticut, United States, 06520 United States, Florida Florida Cancer Specialists - South Fort Myers, Florida, United States, 33916 Florida Cancer Specialists - North Saint Petersburg, Florida, United States, 33705 United States, Illinois University of Chicago Cancer Center Chicago, Illinois, United States, 60637 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Cornell University New York, New York, United States, 10021 Columbia University Medical Center New York, New York, United States, 10032 United States, North Carolina Duke University Durham, North Carolina, United States, 27705 United States, Ohio Ohio State University Columbus, Ohio, United States, 43210 United States, Pennsylvania Temple University Philadelphia, Pennsylvania, United States, 19111 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 Tennessee Oncology Nashville, Tennessee, United States, 37203 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Canada, Ontario Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Less <<
NCT01520805 Acute Myeloid Leukemia (AML) ... More >> Myelodysplastic Syndrome (MDS) Less << Phase 2 Withdrawn December 2018 United States, New Jersey ... More >> Cornerstone Pharmaceuticals, Inc Cranbury, New Jersey, United States, 08512 Less <<
NCT00542828 - Terminated(Study terminated du... More >>e to slow enrollment.) Less << - -
NCT02954653 Acute Myeloid Leukemia Phase 1 Terminated - United States, Arizona ... More >> The University of Arizona Cancer Center-North Campus Tucson, Arizona, United States, 85719 Banner-University Medical Center Tucson Tucson, Arizona, United States, 85724 United States, Illinois The University of Chicago Medical Center Chicago, Illinois, United States, 60637 United States, North Carolina Wake Forest Baptist Health Winston-Salem, North Carolina, United States, 27157 Less <<
NCT01893372 Leukemia Phase 2 Active, not recruiting October 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03298321 - Not yet recruiting October 2020 France ... More >> Service de rythmologie - GH Est-Hôpital Louis Pradel - CHU de Lyon HCL Not yet recruiting Bron, France, 69229 Contact: Philippe CHEVALIER, MD    04 72 35 76 89 ext +33    philippe.chavalier@chu-lyon.fr    Contact: Camille VALLA    04 27 85 62 69 ext +33    camille.valla@chu-lyon.fr    Principal Investigator: Philippe CHEVALIER, MD Less <<
NCT02850822 - Recruiting June 2020 China, Guangdong ... More >> Department of Hematology,Nanfang Hospital, Southern Medical University Recruiting Guangzhou, Guangdong, China, 510515 Contact: Li Xuan    +86-020-61641613    356135708@qq.com    Principal Investigator: Qifa Liu Less <<
NCT02562443 Myelodysplastic Syndrome ... More >> MDS Refractory Anemia With Excess Blasts RAEB Less << Phase 3 Recruiting September 2019 -
NCT02920008 Acute Myeloid Leukemia Phase 3 Active, not recruiting December 2019 -
NCT02348489 Leukemia, Myeloid, Acute Phase 3 Completed - -
NCT03691376 HLA-A*0201 Positive Cells Pres... More >>ent HLA-DP4 Positive Cells Present Platinum-Resistant Ovarian Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Refractory Fallopian Tube Carcinoma Refractory Ovarian Carcinoma Refractory Primary Peritoneal Carcinoma Less << Phase 1 Not yet recruiting October 1, 2020 United States, New York ... More >> Roswell Park Cancer Institute Not yet recruiting Buffalo, New York, United States, 14263 Contact: Kunle Odunsi    716-845-8376    kunle.odunsi@roswellpark.org    Principal Investigator: Kunle Odunsi Less <<
NCT02084563 Acute Myeloid Leukemia ... More >> Myeloproliferative Neoplasms Myelodysplastic Syndromes Myeloproliferative/Myelodysplastic Neoplasm Less << Phase 2 Completed - Brazil ... More >> Hospital Israelita Albert Einstein Sao Paulo, SP, Brazil, 05651901 Less <<
NCT02088541 Acute Myeloid Leukemia (AML) Phase 2 Completed - -
NCT00801489 Acute Myeloid Leukemia With In... More >>v(16)(p13.1q22); CBFB-MYH11 Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 de Novo Myelodysplastic Syndrome High Risk Myelodysplastic Syndrome Inv(16) Myelodysplastic Syndrome With Excess Blasts t(16;16) t(8;21) Untreated Adult Acute Myeloid Leukemia Less << Phase 2 Recruiting April 30, 2020 United States, Texas ... More >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Gautam Borthakur    713-563-1586       Principal Investigator: Gautam Borthakur Less <<
NCT00321711 MDS Myelodysp... More >>lastic Syndromes Thrombocytopenia Less << Phase 2 Completed - -
NCT02723435 Acute Myeloid Leukemia With Ge... More >>ne Mutations Adult Acute Myeloid Leukemia in Remission Less << Phase 2 Withdrawn(Logistical and admin... More >>istrative issues) Less << - -
NCT03164057 Acute Myeloid Leukemia ... More >> Myelodysplastic Syndromes Less << Phase 2 Recruiting June 2027 United States, California ... More >> City of Hope Comprehensive Cancer Center Recruiting Duarte, California, United States, 91010 Contact: Weili Sun, MD,PhD    800-826-4673    weilisun@coh.org    Principal Investigator: Weili Sun, MD,PhD          Children's Hospital of Central California Recruiting Madera, California, United States, 93636 Contact: Faisal Razzaqi, MD    866-353-5437    frazzaqi@valleychildrens.org    Principal Investigator: Faisal Razzaqi, MD          Children's Hospital of Orange County Recruiting Orange, California, United States, 92968 Contact: Jamie Frediani, MD    714-509-4348    jfrediani@choc.org    Principal Investigator: Jamie Frediani, MD          Lucile Packard Children's Hospital Stanford University Recruiting Palo Alto, California, United States, 94304 Contact: Norman J. Lacayo, MD    650-497-8953    lacayon@stanford.edu    Principal Investigator: Norman J. Lacayo, MD          Rady Children's Hospital and Health Center Recruiting San Diego, California, United States, 92123 Contact: Deborah Schiff, MD    858-966-5983    dschiff@chsd.org    Principal Investigator: Deborah Schiff, MD          United States, Tennessee St. Jude Children's Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Tanja A. Gruber, MD, PhD    866-278-5833    tanja.gruber@stjude.org    Contact: Referral Office    866-278-5833    referralinfo@stjude.org    Principal Investigator: Tanja A. Gruber, MD, PhD          United States, Texas Cook Children's Medical Center Recruiting Fort Worth, Texas, United States, 76104 Contact: Kenneth M. Heym, MD    682-885-4007    kenneth.heym@cookchildrens.org    Principal Investigator: Kenneth M. Heym, MD Less <<
NCT02343939 Acute Myeloid Leukemia Phase 1 Phase 2 Active, not recruiting February 2020 United States, California ... More >> UCLA Los Angeles, California, United States United States, Illinois University of Chicago Chicago, Illinois, United States Loyola University Medical Center Maywood, Illinois, United States United States, Indiana Indiana University Indianapolis, Indiana, United States United States, Kansas University of Kansas Medical Center Research Institute, Inc Fairway, Kansas, United States United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States United States, Michigan Henry Ford Health System Detroit, Michigan, United States Karmanos Cancer Institute Detroit, Michigan, United States United States, New York Weill Cornell Medical College - New York - Presbyterian Hospital New York, New York, United States United States, North Carolina Duke Cancer Center Durham, North Carolina, United States United States, Ohio University Hospitals Case Medical Center Cleveland, Ohio, United States Ohio State University Columbus, Ohio, United States United States, Oregon Oregon Health & Science University Portland, Oregon, United States, 97239 United States, South Carolina Saint Francis Cancer Center Greenville, South Carolina, United States Canada, Ontario Princess Margaret Toronto, Ontario, Canada Canada, Quebec Jewish General Hospital Montreal, Quebec, Canada Germany Universitätsklinikum Frankfurt Medizinische Klinik II Frankfurt, Germany, 60590 Less <<
NCT02060409 - Completed - Korea, Republic of ... More >> Samsung Medical Center Seoul, Korea, Republic of Less <<
NCT03356080 Acute Myeloid Leukemia ... More >> Myelodysplastic Syndrome Less << Phase 2 Recruiting July 7, 2020 China ... More >> Beijing Friendship Hospital Not yet recruiting Beijing, China Fujian Medical University Union Hospital Not yet recruiting Fuzhou, China The People's Hospital of Guangxi Zhuang Autonomous Region Not yet recruiting Nanning, China Shanghai Tong Ren hospital Recruiting Shanghai, China Contact: Ligen Liu    18017337037    llg3532@shtrhospital.com    The center hospital of Shanghai Fengxian District Not yet recruiting Shanghai, China First Affiliated Hospital of Zhengzhou University. Not yet recruiting Zhengzhou, China Less <<
NCT02441803 Leukemia Phase 2 Active, not recruiting September 2023 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02272478 Acute Myeloid Leukaemia ... More >> Myelodysplastic Syndrome Less << Phase 2 Phase 3 Recruiting October 2020 United Kingdom ... More >> UHW Recruiting Cardiff, United Kingdom, CF14 4XN Principal Investigator: Steve Knapper          Nottingham University Hospital Recruiting Nottingham, United Kingdom Contact: Nigel Russell, MD Less <<
NCT01241500 Myelodysplastic Syndromes ... More >> MDS RAEB Chronic Myelomonocytic Leukemia Less << Phase 3 Active, not recruiting February 2019 -
NCT01813838 SMD Phase 1 Phase 2 Terminated(Renal toxicity) - France ... More >> Centre hospitalier de la côte Basque Bayonne, France, 64100 Hôpital Avicenne Bobigny, France, 93009 CHU de Haut-Lévèque Bordeaux Pessac, France, 33604 Centre henri Mondor Creteil, France, 94010 CHU de Grenoble Grenoble, France, 38043 CHU de Limoges Limoges, France, 87042 Institut paoli calmettes Marseille, France, 13273 centre hospitalier de Meaux Meaux, France, 77100 CHU de nantes Nantes, France, 44093 Centre Antoine Lacassagne Nice, France, 06189 Hôpital L'archet 1, Nice Nice, France, 06202 cedex 3 Hôpital Saint Louis Paris, France, 75010 Hôpital Saint Antoine Paris, France, 75012 Hôpital Saint-Louis Paris, France, 75475 cedex 10 Hôpital Cochin Paris, France, 75679 cedex14 Centre henri Becquerel Rouen, France, 76038 Hôpital Bretonneau de Tours Tours, France, 37000 Less <<
NCT02886559 AML Relapse Phase 1 Phase 2 Recruiting June 2019 China ... More >> China PLA General Hospital Recruiting Beijing, China, 100039 Contact: Li Yu, M.D Ph.D    010-66937644    chunhuiliyu@yahoo.com    Principal Investigator: Li-Xin Yu Less <<
NCT02323607 Recurrent Adult Acute Myeloid ... More >>Leukemia Secondary Acute Myeloid Leukemia Therapy-Related Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia Less << Phase 1 Suspended(internal data analys... More >>is) Less << September 30, 2018 United States, Ohio ... More >> Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio, United States, 43210 Less <<
NCT02059720 Acute Myeloid Leukemia Phase 3 Unknown December 2018 China, Jiangsu ... More >> The Fisrt Affiliated Hospital of Soochow University Recruiting Suzhou, Jiangsu, China, 215006 Contact: Depei Wu, M.D., Ph.D.    +86 512 6778 1856    wudepei@medmail.com.cn    Contact: Jia Chen, M.D.    +86 512 6778 1856    chenjia@suda.edu.cn    Principal Investigator: Depei Wu, M.D., Ph.D.          Sub-Investigator: Jia Chen, M.D.          Sub-Investigator: Aining Sun, M.D., Ph.D.          Sub-Investigator: Huiying Qiu, M.D., Ph.D.          Sub-Investigator: Xiaowen Tang, M.D., Ph.D.          Sub-Investigator: Yue Han, M.D., Ph.D.          Sub-Investigator: Zhengming Jin, M.D.          Sub-Investigator: Chengcheng Fu, M.D., Ph.D.          Sub-Investigator: Feng Chen, M.D., Ph.D.          Sub-Investigator: Xiao Ma, M.D., Ph.D.          Sub-Investigator: Suning Chen, M.D., Ph.D.          Sub-Investigator: Shengli Xue, M.D., Ph.D.          Sub-Investigator: Xiang Zhang, M.D. Less <<
NCT00321711 - Completed - -
NCT00002831 Leukemia Phase 1 Phase 2 Completed - United States, Texas ... More >> University of Texas - MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03502668 Myelodysplastic Syndromes Phase 1 Phase 2 Recruiting June 2020 United States, Colorado ... More >> University of Colorado, Anschutz Cancer Pavilion Recruiting Aurora, Colorado, United States, 80045 Contact: Daniel Pollyea, MD          Contact: Derek Schatz, BS, CCRP    720-848-0628    derek.schatz@ucdenver.edu    United States, Florida BRCR Medical Center Inc. Recruiting Plantation, Florida, United States, 33324 Contact: Harshad Amin, MD          Contact: Mariaclaudia Reyes    561-447-0614    mreyes@brcrglobal.com    United States, Kansas University of Kansas Clinical Research Center Recruiting Westwood, Kansas, United States, 66205 Contact: Abdulraheem Yacoub, MD          United States, Michigan Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Jay Yang, MD    313-576-8952    yangj@karmanos.org    Contact: Christiane Houde, BS    313-576-9381    houdec@karmanos.org Less <<
NCT02281084 Myelodysplastic Syndromes Phase 2 Active, not recruiting June 18, 2019 -
NCT01812252 Chronic Myelomonocytic Leukemi... More >>a de Novo Myelodysplastic Syndrome Myelodysplastic Syndrome Secondary Myelodysplastic Syndrome Less << Phase 2 Recruiting - United States, Arizona ... More >> Mayo Clinic in Arizona Recruiting Scottsdale, Arizona, United States, 85259 Contact: Mayo Clinic Clinical Trials Office    855-776-0015    cancerclinicaltrials@mayo.edu    Principal Investigator: Nandita Khera          United States, Ohio Cleveland Clinic Foundation Recruiting Cleveland, Ohio, United States, 44195 Contact: Aaron T. Gerds    216-444-6833    gerdsa@ccf.org    Principal Investigator: Aaron T. Gerds          United States, Washington Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Bart L. Scott    206-667-1990    bscott@fhcrc.org    Principal Investigator: Bart L. Scott          Kaiser Permanente Washington Terminated Seattle, Washington, United States, 98112 Less <<
NCT01546038 Acute Myeloid Leukemia Phase 2 Active, not recruiting June 2019 -
NCT03771222 Donor Lymphocyte Infusion ... More >> Peripheral Blood Stem Cell Transplantation Relapse Graft-versus-host Disease Decitabine Less << Phase 2 Not yet recruiting December 2021 China, Beijing ... More >> Chinese PLA General Hospital Beijing, Beijing, China, 100853 Less <<
NCT03184935 Myelodysplastic Syndromes Phase 1 Phase 2 Not yet recruiting September 2018 China, Inner Mongolia ... More >> Inner Mongolia International Mongolian Hospital Not yet recruiting Hohhot, Inner Mongolia, China, 010065 Contact: Wulantuya    864715182155 Less <<
NCT03366116 Neoplasms Sol... More >>id Tumors Less << Phase 1 Recruiting September 23, 2021 United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    888-624-1937 Less <<
NCT01546038 - Active, not recruiting - -
NCT03132454 Hematopoietic/Lymphoid Cancer ... More >> Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Less << Phase 1 Recruiting July 2021 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact       tkadia@mdanderson.org Less <<
NCT03092674 Acute Myeloid Leukemia ... More >> Myelodysplastic Syndrome Myelodysplastic Syndrome With Excess Blasts-2 Untreated Adult Acute Myeloid Leukemia Less << Phase 2 Phase 3 Suspended(Other - Safety data ... More >>review, unscheduled) Less << August 1, 2023 -
NCT03226418 Adult Acute Myeloid Leukemia ... More >> Secondary Acute Myeloid Leukemia Therapy-Related Acute Myeloid Leukemia Less << Phase 2 Recruiting July 7, 2023 United States, California ... More >> USC / Norris Comprehensive Cancer Center Not yet recruiting Los Angeles, California, United States, 90033 Contact: Mojtaba Akhtari       mojtaba.akhtari@med.usc.edu    Principal Investigator: Mojtaba Akhtari          United States, Nebraska University of Nebraska Medical Center Recruiting Omaha, Nebraska, United States, 68198 Contact: Vijaya R. Bhatt    402-559-8008    vijaya.bhatt@unmc.edu    Principal Investigator: Vijaya R. Bhatt Less <<
NCT02197676 MDS Phase 2 Completed - France ... More >> CH Angers Angers, France, 49 000 CH Avignon Avignon, France, 84000 Centre Hospitalier de La Cote Basque Bayonne, France, 64100 Hôpital Avicenne Bobigny, France, 93 000 CHU Clémenceau Caen, France, 14033 CHU Henri Mondor Créteil, France, 94010 CHU de Grenoble Grenoble, France, 38043 Centre Hospitalier du Mans Le Mans, France, 72000 CHRU Limoges Limoges, France, 87046 CH Lyon Sud Lyon, France, 69495 Hôpital Paoli Calmettes Marseille, France, 13273 Centre Hospitalier de Meaux Meaux, France, 77100 Clinique Beausoleil (Montpellier) Montpellier, France, 34000 CHU de nantes Nantes, France, 44093 Centre Catherine de Sienne (Nantes) Nantes, France, 44277 CHU de Nice - Hopital de l'Archet 1 Nice, France, 06 202 CHR Orléans Orléans, France, 45000 Hopital St Louis T4 Paris, France, 75475 Centre Hospitalier Joffre Perpignan, France, 66046 CHU de Haut-Lévèque Pessac, France, 33604 CHU de Poitiers Poitiers, France, 86000 Centre Hospitalier de la région d'Annecy Pringy, France, 74374 Centre Henri Becquerel Rouen, France, 76038 Chu Purpan Toulouse, France, 31059 Hopital Purpan Service d'Hématologie Clinique Toulouse, France CHU Bretonneau Tours, France, 37044 CHU Brabois Vandœuvre-lès-Nancy, France, 54511 Less <<
NCT01483274 Acute Myelogenous Leukemia Phase 1 Withdrawn(Adult patient popula... More >>tion barriers.) Less << - United States, Kentucky ... More >> University of Louisville Louisville, Kentucky, United States, 40202 Less <<
NCT01993641 Myelodysplastic Syndrome ... More >> MDS Less << Phase 2 Completed - United States, Alabama ... More >> Southern Cancer Center Mobile, Alabama, United States, 36608 United States, California City of Hope Duarte, California, United States, 91010 USC Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 Sutter Medical Group Sacramento, California, United States, 95816 United States, Colorado Colorado Blood Cancer Institute Denver, Colorado, United States, 80218 United States, Connecticut Yale School of Medicine New Haven, Connecticut, United States, 06520 United States, Florida Florida Cancer Specialist South Fort Myers, Florida, United States, 33916 Florida Cancer Specialist North St Petersburg, Florida, United States, 33705 United States, Illinois Northwestern University Chicago, Illinois, United States, 60601 United States, Kansas University of Kansas Cancer Center Westwood, Kansas, United States, 66205 United States, Kentucky University of Kentucky Lexington, Kentucky, United States, 40536 United States, New Jersey John Theurer Cancer Center Hackensak, New Jersey, United States, 07601 United States, Ohio Oncology Hematology Care Cincinati, Ohio, United States, 45242 Cleveland Clinic Cleveland, Ohio, United States, 44195 United States, Oklahoma University of Oklahoma Health Science Center Oklahoma City, Oklahoma, United States, 73104 United States, Tennessee Tennessee Oncology-Chattanooga Chattanooga, Tennessee, United States, 37404 Tennessee Oncology Nashville, Tennessee, United States, 37203 United States, Texas Baylor University Medical Center Dallas, Texas, United States, 75246 University of Texas Southwestern Dallas, Texas, United States, 75390 MD Anderson Cancer Center Houston, Texas, United States, 77030 Cancer Care Centers of South Texas San Antonio, Texas, United States, 78229 Less <<
NCT02412475 Leukemia, Acute Myeloid Phase 1 Active, not recruiting February 2019 United States, Minnesota ... More >> Children's Hospitals and Clinics of Minnesota Minneapolis, Minnesota, United States, 55404 United States, Wisconsin Children's Hospital of Wisconsin Milwaukee, Wisconsin, United States, 53226 Less <<
NCT03530085 Acute Myeloid Leukemia ... More >> Allogeneic Hematopoietic Stem Cell Transplantation Conditioning Elderly Less << Phase 2 Phase 3 Recruiting April 2022 China, Guangdong ... More >> Department of Hematology,Nanfang Hospital, Southern Medical University Recruiting Guangzhou, Guangdong, China, 510515 Contact: Li Xuan    +86-020-62787883    356135708@qq.com    Principal Investigator: Qifa Liu Less <<
NCT03417427 Leukemia, Myeloid Phase 2 Recruiting January 31, 2025 China, Guangdong ... More >> Nanfang Hospital of Southern Medical University Recruiting Guanzhou, Guangdong, China, 510515 Contact: Xuejie Jiang, doctor    +8618688869522    jxj3331233@163.com Less <<
NCT03453255 Chemotherapy Phase 1 Phase 2 Recruiting December 31, 2020 China ... More >> Chinese PLA General Hospital Recruiting Beijing, China, 100853 Contact: Li Yu, M.D. Ph.D.    86-010-55499003    chunhuiliyu@yahoo.com    Principal Investigator: Li Yu, M.D. Ph.D. Less <<
NCT02802267 Acute Myelogenous Leukemia Phase 2 Recruiting December 2019 United States, California ... More >> Scripps Health Recruiting San Diego, California, United States, 92103 Contact: Marin Xavier, M.D.          Contact: Boyka S Petrov       Petrov.Boyka@scrippshealth.org    United States, Georgia Georgia Cancer Center-Augusta University Recruiting Augusta, Georgia, United States, 30912 Contact: Jeremy M Pantin, M.D.          Contact: Christine Sanchez       csanchez@augusta.edu    United States, Nevada Comprehensive Cancer Centers of Nevada Recruiting Las Vegas, Nevada, United States, 89169 Contact: Khin Win, MBBS, CCRC       khin.win@usoncology.com    Contact: Tiffany Gordon       tiffany.gordon@usoncology.com    Principal Investigator: Edwin Kingsley, MD          United States, New Mexico New Mexico Cancer Care Alliance Recruiting Albuquerque, New Mexico, United States, 87106 Contact: Kaylee Deutsch, MHA, CCRP       kdeutsch@nmcca.org    Contact: April Encee, RN, OCN       aencee@salud.unm.edu    Principal Investigator: Cecilia Arana-Yi, MD          United States, North Carolina Duke Cancer Institute, Duke Univ Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: David Rizzieri, M.D.          Contact: Rachel Stowe       rachel.stowe@duke.edu    United States, Texas University of Texas; M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Jorge Cortes, M.D.          Contact: Jane A Autry       JAAutry@mdanderson.org    United States, Wisconsin ProHealth Care Inc Not yet recruiting Waukesha, Wisconsin, United States, 53188 Contact: Dawn Minikel       dawn.minikel@phci.org    Contact: Amelia Crouse       amelia.crouse@phci.org    Principal Investigator: Timothy Wassenaar, MD          France Necker Hospital- APHP Recruiting Paris, France, 75015 Contact: Olivier Hermine, MD, PhD Less <<
NCT02488408 Acute Myeloid Leukemia ... More >> Myelodysplastic Syndromes Less << Phase 1 Phase 2 Recruiting August 2018 United States, Iowa ... More >> University of Iowa Hospitals and Clinics Recruiting Iowa City, Iowa, United States, 52242 Contact: Karen Parrott    319-353-6347    karen-parrott@uiowa.edu    Principal Investigator: Carlos E Vigil, MD          United States, Ohio James Cancer Hospital & Solove Research Institute Recruiting Columbus, Ohio, United States, 43210 Contact: Molly Vittorio    614-293-7940    molly.vittorio@osumc.edu    Principal Investigator: William Blum, Professor          United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Cora Cheung    713-792-3461    cmcheung@mdanderson.org    Principal Investigator: Jorge Cortes, Professor          Germany Universitätsklinikum Frankfurt, Medizinische Klinik II Recruiting Frankfurt, Germany, 60596 Contact: Laura Hefermehl    +49 69 6301 86708    Laura.Hefermehl@kgu.de    Principal Investigator: Jörg Chromik, Dr          University Medical Center Hamburg-Eppendorf Martinistrasse Recruiting Hamburg, Germany, 20246 Contact: Sonja T Loges, MD, PhD    +49 407-410-51969    s.loges@uke.de    Principal Investigator: Sonja Loges, MD, PhD          Medizinische Hochschule Hannover Recruiting Hannover, Germany, 30625 Contact: Gabriele Samson    +49 (511) 532 9321    samson.gabriele@mh-hannover.de    Principal Investigator: Michael Heuser, Dr          Universitätsklinikum Ulm, Oberer Eselsberg, Zentrum für Innere Medizin III Recruiting Ulm, Germany, 89081 Contact: Manuela Wetzel    +49 (0) 731 500 45709    manuela.wetzel@uniklinik-ulm.de    Principal Investigator: Peter Paschka, Dr          Norway Haukeland University Hospital Recruiting Bergen, Norway, 5021 Contact: Marianne Emblem Lehmann    +47 59972890/ 95975516    marianne.emblem.lehmann@helse-bergen.no    Principal Investigator: Bjørn Tore Gjertsen, Professor Less <<
NCT02190695 Acute Myeloid Leukemia ... More >> Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia Less << Phase 2 Recruiting April 2018 United States, Pennsylvania ... More >> Temple BMT Program at Jeanes Hospital Recruiting Philadelphia, Pennsylvania, United States, 19111 Principal Investigator: Patricia Kropf, MD          Principal Investigator: Jean-Pierre Issa, MD          Sub-Investigator: Stefan Barta, MD          Sub-Investigator: Philip Pancari, MD          Sub-Investigator: Henry Fung, MD          United States, Texas M.D. Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 Contact: Alexandra Thackrey, RN- BC    713-745-2238    AMThackrey@mdanderson.org    Principal Investigator: Hagop Kantarjian, MD Less <<
NCT02085408 Acute Myeloid Leukemia With Mu... More >>ltilineage Dysplasia Following Myelodysplastic Syndrome Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Secondary Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia Less << Phase 3 Active, not recruiting - -
NCT01690507 MDS AML Phase 1 Phase 2 Completed - China, Beijing ... More >> Navy General Hospital Beijing, Beijing, China, 100048 China Chinese PLA General Hospital Beijing, China, 100853 Less <<
NCT00037817 Advanced Esophageal Cancers ... More >> Primary Small Cell Lung Cancers Non-Small-Cell Lung Carcinoma Pleural Mesotheliomas Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura Less << Phase 1 Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00715793 - Completed - -
NCT00715793 Malignant Melanoma Phase 1 Phase 2 Completed - United States, Pennsylvania ... More >> UPMC Cancer Centers Pittsburgh, Pennsylvania, United States, 15232 Less <<
NCT03233724 Carcinoma, Non-Small-Cell Lung... More >> Lung Cancer Non-Small Cell Lung Cancer Less << Phase 1 Phase 2 Recruiting December 31, 2020 United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    888-624-1937 Less <<
NCT01928537 Myelodysplastic Syndromes ... More >> Refractory Anemia With Excess Blasts Chronic Myelomonocytic Leukemia Cytopenia Less << Phase 3 Active, not recruiting February 2019 -
NCT02839694 Neoplasm Metastasis ... More >> Sarcoma Neoplasms, Germ Cell and Embryonal Melanoma Less << Phase 1 Withdrawn - -
NCT01674985 Myelodysplastic Syndromes Phase 1 Phase 2 Completed - China, Beijing ... More >> Affiliated Hospital of Academy of Military Medical Sciences Beijing, Beijing, China, 100071 Less <<
NCT01165996 - Completed - -
NCT01303796 Acute Myeloid Leukemia Phase 3 Completed - -
NCT00740181 Myelodysplasia ... More >> Leukemia Less << Phase 2 Terminated(Lack of efficacy) - United States, Rhode Island ... More >> Lifespan Hospitals Providence, Rhode Island, United States, 02903 Less <<
NCT00740181 - Terminated(Lack of efficacy) - -
NCT00879385 Colorectal Cancer Phase 1 Completed - United States, Utah ... More >> Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 Less <<
NCT03752138 Recurrent Acute Myeloid Leukem... More >>ia Refractory Acute Myeloid Leukemia Less << Phase 1 Not yet recruiting December 31, 2020 United States, Texas ... More >> M D Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 Contact: Tapan M. Kadia    713-563-3534       Principal Investigator: Tapan M. Kadia Less <<
NCT01673217 Recurrent Fallopian Tube Cance... More >>r Recurrent Ovarian Epithelial Cancer Recurrent Primary Peritoneal Cavity Cancer Less << Phase 1 Completed - United States, New York ... More >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Less <<
NCT01707004 Acute Myeloid Leukemia With Mu... More >>ltilineage Dysplasia Following Myelodysplastic Syndrome Adult Acute Myeloid Leukemia in Remission Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) de Novo Myelodysplastic Syndromes Previously Treated Myelodysplastic Syndromes Recurrent Adult Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Less << Phase 2 Completed - United States, Wisconsin ... More >> University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 Less <<
NCT01165996 Chronic Myelomonocytic Leukemi... More >>a de Novo Myelodysplastic Syndromes Myelodysplastic Syndromes Refractory Anemia Refractory Anemia With Excess Blasts Refractory Anemia With Ringed Sideroblasts Refractory Cytopenia With Multilineage Dysplasia Thrombocytopenia Less << Phase 1 Phase 2 Completed - United States, Ohio ... More >> Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106 Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 Less <<
NCT03146871 Acute Myeloid Leukemia Arising... More >> From Previous Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia Previously Treated Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes Recurrent Adult Acute Myeloid Leukemia Less << Phase 2 Recruiting April 20, 2021 United States, California ... More >> USC / Norris Comprehensive Cancer Center Recruiting Los Angeles, California, United States, 90033 Contact: Ibrahim L. Syed    323-865-3928    Ibrahim.Syed@med.usc.edu    Principal Investigator: Casey L. O'Connell, MD Less <<
NCT02204085 Acute Myeloid Leukemia, in Rel... More >>apse Recurrent Adult Acute Myeloid Leukemia Less << Phase 1 Phase 2 Recruiting July 2021 United States, Massachusetts ... More >> Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 Contact: Richard M. Stone, MD    617-632-2214    rstone@partners.org    Principal Investigator: Richard Stone, MD          Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02215 Contact: David Avigan, MD    617-667-9920    davigan@bidmc.harvard.edu    Principal Investigator: David Avigan, MD Less <<
NCT02469415 - Terminated(FDA Clinical Hold) - -
NCT03679650 Acute Myelogenous Leukemia Phase 1 Recruiting August 31, 2024 United States, Massachusetts ... More >> Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02215 Contact: Emma Logan, BSN    617-667-5984    eklogan@bidmc.harvard.edu    Principal Investigator: Jacalyn Rosenblatt, MD          Dana Farber Cancer Institute Not yet recruiting Boston, Massachusetts, United States, 02215 Contact: Robert J Soiffer, MD       Robert_soiffer@dfci.harvard.edu    Principal Investigator: Robert J Soiffer, MD Less <<
NCT02469415 Leukemia Phase 2 Terminated(FDA Clinical Hold) - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01211457 Acute Myeloid Leukemia Phase 1 Phase 2 Active, not recruiting June 2020 United States, Illinois ... More >> Rush University Medical Center Chicago, Illinois, United States, 60612 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030-3387 Less <<
NCT00041990 Chronic Myelogenous Leukemia Phase 2 Completed - United States, California ... More >> City of Hope Medical Center Duarte, California, United States Scripps Clinic Escondido, California, United States USC/Norris Cancer Center Los Angeles, California, United States United States, Minnesota Metro-Minnesota CCOP St. Louis Park, Minnesota, United States United States, New York New York Medical College Valhalla, New York, United States United States, South Carolina Liberty Hematology/Oncology Columbia, South Carolina, United States United States, Texas University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Canada, Ontario Princess Margaret Hospital Toronto, Ontario, Canada Less <<
NCT00002980 Chronic Myeloproliferative Dis... More >>orders Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Precancerous Condition Unspecified Adult Solid Tumor, Protocol Specific Less << Phase 1 Completed - United States, California ... More >> Beckman Research Institute, City of Hope Duarte, California, United States, 91010 USC/Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033-0800 Los Angeles County-University of Southern California Medical Center Los Angeles, California, United States, 90033 University of California Davis Cancer Center Sacramento, California, United States, 95817 Less <<
NCT02662647 AML Phase 2 Recruiting December 2019 China, Beijing ... More >> Navy General Hospital Recruiting Beijing, Beijing, China, 100048 Contact: Li-Xin Wang, M.D Ph.D    86-010-66958509    wanglixin1991@sohu.com    Principal Investigator: Li-Xin Wang, M.D. Ph.D. Less <<
NCT00492401 Adult Acute Myeloid Leukemia W... More >>ith 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Secondary Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia Less << Phase 2 Completed - United States, Ohio ... More >> Ohio State University Medical Center Columbus, Ohio, United States, 43210 Less <<
NCT00042003 Chronic Myelogenous Leukemia Phase 2 Completed - United States, California ... More >> City of Hope Medical Center Duarte, California, United States Scripps Clinic Escondido, California, United States USC/Norris Cancer Center Los Angeles, California, United States United States, Minnesota Metro-Minnesota CCOP St. Louis Park, Minnesota, United States United States, New York New York Medical College Valhalla, New York, United States United States, South Carolina Liberty Hematology/Oncology Columbia, South Carolina, United States United States, Texas University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Canada, Ontario Princess Margaret Hospital Toronto, Ontario, Canada Less <<
NCT00075634 Recurrent Neuroblastoma ... More >> Unspecified Childhood Solid Tumor, Protocol Specific Less << Phase 1 Completed - United States, California ... More >> Children's Oncology Group Arcadia, California, United States, 91006-3776 Less <<
NCT01041846 - Completed - -
NCT00042016 Chronic Myelogenous Leukemia Phase 2 Completed - United States, California ... More >> City of Hope Medical Center Duarte, California, United States Scripps Clinic Escondido, California, United States USC/Norris Cancer Center Los Angeles, California, United States United States, Minnesota Metro-Minnesota CCOP St. Louis Park, Minnesota, United States United States, New York New York Medical College Valhalla, New York, United States United States, South Carolina Liberty Hematology/Oncology Columbia, South Carolina, United States United States, Texas University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Canada, Ontario Princess Margaret Hospital Toronto, Ontario, Canada Less <<
NCT03263936 Acute Myelogenous Leukemia Phase 1 Recruiting July 2020 -
NCT00019825 Esophageal Cancer ... More >> Lung Cancer Malignant Mesothelioma Metastatic Cancer Less << Phase 1 Completed - United States, Maryland ... More >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 Center for Cancer Research Bethesda, Maryland, United States, 20892 Less <<
NCT00114257 Chronic Myeloproliferative Dis... More >>orders Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Less << Phase 1 Completed - United States, Texas ... More >> M.D. Anderson Cancer Center at University of Texas Houston, Texas, United States, 77030-4009 Less <<
NCT00492401 - Completed - -
NCT01696032 Ovarian Cancer Phase 2 Completed - -
NCT02608437 Metastatic Melanoma Phase 1 Unknown October 2018 Italy ... More >> Medical Oncology and Immunotherapy Unit, University Hospital of Siena Recruiting Siena, Italy, 53100 Contact: Anna Maria Di Giacomo, PhD, MD    +390577586305    a.m.digiacomo@ao-siena.toscana.it    Contact: Giovanni Amato, PhD    +390577586326    dataman.immonco@ao-siena.toscana.it Less <<
NCT02072811 Acute Myeloid Leukemia Phase 3 Unknown February 2018 Poland ... More >> Copernicus Memorial Hospital Recruiting Lodz, Poland, 93-510 Principal Investigator: Agnieszka Wierzbowska, Dr hab. n. med. Less <<
NCT03701295 Acute Myeloid Leukemia With t(... More >>9;11)(p21.3;q23.3); MLLT3-KMT2A Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Less << Phase 1 Phase 2 Not yet recruiting November 1, 2020 -
NCT03680677 Leukemia, Acute ... More >> MDS Less << Not Applicable Not yet recruiting November 2025 United States, Pennsylvania ... More >> Abramson Cancer Center of the University of Pennsylvania Not yet recruiting Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT02551718 Acute Leukemia of Ambiguous Li... More >>neage Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Refractory Adult Acute Lymphoblastic Leukemia Refractory Childhood Acute Lymphoblastic Leukemia Less << Not Applicable Recruiting - United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Pamela S. Becker    206-616-1589    pbecker@u.washington.edu    Principal Investigator: Pamela S. Becker Less <<
NCT02892318 Acute Myeloid Leukemia Phase 1 Suspended(Study enrollment on ... More >>hold to evaluate safety and efficacy data.) Less << January 31, 2019 United States, California ... More >> City of Hope Duarte, California, United States, 91010 United States, Connecticut Yale University New Haven, Connecticut, United States, 06511 United States, New York The NewYork-Presbyterian Hospital Columbia University Medical Center New York, New York, United States, 10032 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Levine Cancer Institute Charlotte, North Carolina, United States, 28204 United States, Pennsylvania Temple University Hospital Philadelphia, Pennsylvania, United States, 19140 United States, Utah Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 United States, Wisconsin The University of Wisconsin School of Medicine and Public Health Madison, Wisconsin, United States, 53705 Less <<
NCT00906334 Myelodysplastic Syndrome Phase 2 Completed - United States, California ... More >> Stanford Cancer Center Stanford, California, United States, 94305 Less <<
NCT02845232 - Completed - France ... More >> Hospices Civils de Lyon - Centre Hospitalier Lyon Sud, 165 Chemin du Grand Revoyet Pierre-benite, France, 69310 Less <<
NCT03687463 Hematopoietic System--Cancer UNKNOWN 2020-04-10 -
NCT03828084 Healthy PHASE1 COMPLETED 2019-05-03 Worldwide Clinical Trial, San ... More >>Antonio, Texas, 78217, United States Less <<
NCT04854889 Refractory Aplastic Anemia PHASE2 TERMINATED 2022-08-09 Regenerative Medicine Center, ... More >>Tianjin, Tianjin, China Less <<
NCT04086238 Healthy PHASE1 COMPLETED 2019-11-30 Worldwide Clinical Trial, San ... More >>Antonio, Texas, 78217, United States Less <<
NCT00260065 Myelodysplastic Syndrome PHASE2 COMPLETED 2025-12-08 Birmingham, Alabama, 35235, Un... More >>ited States|Phoenix, Arizona, United States|Boca Raton, Florida, 33486, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|New Port Richey, Florida, 34652, United States|Griffin, Georgia, 30224, United States|Chicago, Illinois, 60637-1470, United States|Maywood, Illinois, 60153, United States|Rochester, Minnesota, 55905, United States|Hackensack, New Jersey, 07601, United States|Buffalo, New York, 14263, United States|Canton, Ohio, 44718, United States|Charleston, South Carolina, 29406, United States|Memphis, Tennessee, 38138, United States|Houston, Texas, 77030, United States|Midland, Texas, 79701, United States|Seattle, Washington, 98104, United States|La Crosse, Wisconsin, 54601, United States|Milwaukee, Wisconsin, 53215, United States|Toronto, Ontario, M4N 3M5, Canada Less <<
NCT00398983 Acute Myelogenous Leukemia PHASE2|PHASE3 COMPLETED 2025-05-12 UT MD Anderson Cancer Center, ... More >>Houston, Texas, 77030, United States Less <<
NCT01375608 Neutropenia|Sickle Cell Diseas... More >>e Less << PHASE2 COMPLETED 2025-02-16 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT00358644 Acute Myeloid Leukemia PHASE2 COMPLETED 2025-12-08 Duarte, California, 91010, Uni... More >>ted States|Los Angeles, California, 90095-1678, United States|St. Louis, Missouri, 63110, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.38mL

0.88mL

0.44mL

21.91mL

4.38mL

2.19mL

43.82mL

8.76mL

4.38mL

References

 

Historical Records

Categories